
TITLE: untitled
SOURCE: Brain Imaging in Alzheimer Disease.pdf
AUTHOR: 

===== DOCUMENT CONTENT =====

Brain Imaging in Alzheimer Disease KeithA.Johnson1,NickC.Fox2,ReisaA.Sperling3,andWilliamE.Klunk4 1DepartmentsofRadiologyandNeurology,MassachusettsGeneralHospital,BrighamandWomen’s Hospital,HarvardMedicalSchool,Boston,Massachusetts02114 2DementiaResearchCentre,UCLInstituteofNeurology,UniversityCollege,LondonWCIN3AR, UnitedKingdom 3CenterforAlzheimerResearchandTreatment,BrighamandWomen’sHospital,MassachusettsGeneral Hospital,HarvardMedicalSchool,Boston,Massachusetts02115 4DepartmentsofPsychiatryandNeurology,UniversityofPittsburghSchoolofMedicine,Pittsburgh, Pennsylvania15213 Correspondence:klunkwe@upmc.edu ImaginghasplayedavarietyofrolesinthestudyofAlzheimerdisease(AD)overthepastfour decades.Initially,computedtomography(CT)andthenmagneticresonanceimaging(MRI) wereuseddiagnosticallytoruleoutothercausesofdementia.Morerecently,avarietyof imagingmodalitiesincludingstructuralandfunctionalMRIandpositronemissiontomogra- phy(PET)studiesofcerebralmetabolismwithfluoro-deoxy-D-glucose(FDG)andamyloid tracers such as Pittsburgh Compound-B (PiB) have shown characteristic changes in the brains of patients with AD, and in prodromal and even presymptomatic states that can helprule-intheADpathophysiologicalprocess.Nooneimagingmodalitycanserveallpur- posesaseachhaveuniquestrengthsandweaknesses.Thesemodalitiesandtheirparticular utilitiesarediscussedinthisarticle.Thechallengeforthefuturewillbetocombineimaging biomarkerstomost efficientlyfacilitate diagnosis,diseasestaging,and,most importantly, developmentofeffectivedisease-modifyingtherapies. THECHANGINGROLESANDSCOPE ADanditstemporalandspatialevolution.Fur- OFNEUROIMAGINGINALZHEIMER thermore,imagingisanestablishedtoolindrug DISEASE discovery, increasingly required in therapeutic trials as part of inclusion criteria, as a safety There has been a transformation in the part marker,andasanoutcomemeasure. played by neuroimaging in Alzheimer dis- Concomitantlythepotentialofbrainimag- ease(AD)researchandpracticeinthelastdec- ing has expanded rapidly with new modalities ades.Diagnostically,imaginghasmovedfroma andnovelwaysofacquiringimagesandofana- minorexclusionaryroletoacentralposition.In lysingthem.Thisarticlecannotbecomprehen- research, imaging is helping address many of sive. Instead, it addresses broad categories of thescientificquestionsoutlined inSelkowet al. structural, functional, and molecular imaging (2011): providing insights into the effects of in AD. The specific modalities included are Editors:DennisJ.Selkoe,EckhardMandelkow,andDavidM.Holtzman AdditionalPerspectivesonTheBiologyofAlzheimerDiseaseavailableatwww.perspectivesinmedicine.org Copyright#2012ColdSpringHarborLaboratoryPress;allrightsreserved;doi:10.1101/cshperspect.a006213 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 1 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. magneticresonanceimaging(MRI;bothstruc- et al. 2004). Obviously, it would be of great tural and functional) and positron emission valuetobeabletopredictwhichMCIsubjects tomography(PET;forassessmentofbothcere- weredestinedtoprogresstoaclinicaldiagnosis bral metabolism and amyloid). These modal- of AD. This is true even in the absence of ities have different strengths and limitations disease-modifyingtreatments,butwillbeespe- andasaresulthavedifferentandoftencomple- cially critical when disease-modifying treat- mentaryrolesandscope. mentsbecomeavailable. Looking to the future, imaging has helped establish that there is a long preclinical and ImagingintheDiagnosisandPrognosisofAD presymptomaticperiodwherethepathological Theuncertaintyinherentinaclinicaldiagnosis effects of AD are detectable. Although more ofADhasdrivenasearchfordiagnosticimag- dataareneeded,imagingisstartingtoprovide ing markers. A definitive diagnosis still re- prognosticinformationatthisearlypreclinical quires histopathological confirmation and the stage. The need for an earlier and more cer- inaccessibilityof the brain means imaging has tain diagnosis will only increase as disease- akeyroleasa“windowonthebrain.”Histori- modifying therapies are identified. This will cally, imaging-first computed tomography beparticularlytrueif,asexpected,thesethera- (CT)andthenMRI-wasusedonlytoexclude pies work best (or only) when initiated at the potentiallysurgically treatablecausesofcogni- preclinicalstage. tive decline. Now its position in diagnosis also includes providing positive support for a UnderstandingtheBiologyofAD clinical diagnosis of AD in symptomatic indi- Importantly,imaginghasamajorroletoplayin viduals by identifying characteristic patterns improvingourunderstandingofthisdisease(or (signatures) of structural and functional cere- diseases).Uniquely,imagingisabletodelineate bral alterations. We can now alsovisualize the inlifethelocationwithinthebrainoftheeffects specific molecular pathology of the disease- ofAD.Together withthistopographicalinfor- amyloid deposits-with amyloid imaging. mationimagingcanquantifymultipledifferent Alongside this increasing specificity for AD, aspects of AD pathology and assess how they imagingalsocontributestodifferentialdiagno- relate to each otherand how they change over sisinpracticebyidentifyingalternativeand/or time.Theclinicalcorrelationsofthesechanges contributory pathologies. Imaging is central and their relationships to other biomarkers to identifying vascularand non-AD degenera- and to prognosis can be studied. Ultimately tivepathologiesandhashelpedintherecogni- the role of imaging in improving our under- tion of the prevalence of mixed pathology in standingofthebiologyofADunderpinsallits dementia. applications and is a theme that runs through Inthesettingofmildcognitiveimpairment thefollowingsectionsofthisarticle. (MCI) (Petersen 2004), the determination of underlying pathology carries immediate prog- nostic importance. Only a fraction of patients STRUCTURALMRIINAD with MCI progress to clinical AD over 5-10 BasicsofStructuralMRIasAppliedtoAD years (Petersen et al. 1999; Ritchie et al. 2001; Visser et al. 2006) and a recent meta-analysis MRIutilizesthefactthatprotonshaveangular concludedthatmostpeoplewithMCIwillnot momentum which is polarized in a magnetic progress to dementia even after 10 years of field.Thismeansthatapulseofradiofrequency follow-up (Mitchell and Shiri-Feshki 2009). canaltertheenergystateofprotonsand,when Two community-based studies have shown the pulse is turned off, the protons will, on over one-third of patients diagnosed with returningtotheirenergystage,emitaradiofre- MCI at baseline mayeventually return to nor- quencysignal.Byacombinationofdifferentgra- mal cognition (Larrieu et al. 2002; Ganguli dientsandpulses,“sequences”canbedesigned 2 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease tobesensitivetodifferenttissuecharacteristics. dendritic and neuronal losses. Studies of re- InbroadtermsstructuralMRIinADcanbediv- gional (e.g., hippocampal) MRI volumes have ided into assessing atrophy (or volumes) and shown these are closely related to neuronal changes in tissue characteristics which cause countsatautopsy(Bobinskietal.2000;Gosche signal alterations on certain sequences such as etal.2002;Jacketal.2002).Thepatternofloss white matter hyperintensities on T2-weighted differs between diseases reflecting selective MRIasa resultofvasculardamage.A number neuronal vulnerabilityand/or regional disease of MR sequences that are sensitive to micro- expression.ADischaracterizedbyaninsidious structural change (e.g., magnetization transfer onset and inexorable progression of atrophy or diffusion) have shown alterations in AD. that is first manifest in the medial temporal Thesesequencesarealreadyimportantresearch lobe(Scahilletal.2002).Theentorhinalcortex tools;however,theyhavenotyetfounda place is typically the earliest site of atrophy, closely inroutineclinicalpracticeinADandtheywill followed by the hippocampus, amygdala, and notbeconsideredfurtherhere. parahippocampus (Lehericy et al. 1994; Chan etal.2001;Dickersonetal.2001;Killianyetal. 2002). Other structures within the limbic lobe UtilityofStructuralMRIintheStudyofAD suchastheposteriorcingulatearealsoaffected earlyon.Theselossesthenspreadtoinvolvethe AtrophyinAD temporal neocortex and then all neocortical Progressive cerebral atrophy is a characteristic associationareasusuallyinasymmetricalfash- featureofneurodegenerationthatcanbevisual- ion. This sequence of progression of atrophy ized in life with MRI (best with T1-weighted onMRImostcloselyfitshistopathologicalstud- volumetric sequences; see Fig. 1). The major ies that have derived stages for the spread of contributors to atrophy are thought to be neurofibrillarytangles(BraakandBraak1991). H t = 0 t = 1y t = 2y Figure1.ThisseriesofthreecoronalT1-weightedstudies,fromanindividualwithautopsy-provenAlzheimer disease(AD),wereeachacquired(cid:2)1yrapartandshowprogressivehippocampal(H)atrophyastheindividual progressed from memory complaints (left column, t¼0) to MCI (center, t¼1y) and on to fulfill criteria forAD. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 3 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. Nonetheless,asignificantminorityofADcases (prodromal) AD at a pre-dementia stage have atypical presentations and in these cases (Duboisetal.2007).Theseverityofhippocam- thepatternofatrophyaccordswithclinicalphe- pal atrophy tends to be greater in AD than in notype: with language presentations particu- dementiawith Lewy bodies (DLB) or vascular larly having left temporal atrophy and visual dementia (VaD)-when matched for clinical variantshavingposteriorcorticalatrophy. severity. Nonetheless, hippocampal atrophy is It is increasingly clear that by the time a afeatureofDLBandVaD,andinfrontotempo- typical ADpatientcomestodiagnosis atrophy raldementia(FTD)canbemoresevereanteri- iswellestablished.Eveninmildlyaffectedindi- orly than in AD (Barber et al. 2000; Chan viduals(e.g.,meanMMSEof(cid:2)24/30)entorhi- et al. 2001; McKeith et al. 2005; Burton et al. nalvolumesarealreadyreducedby (cid:2)20-30% 2009). The differential diagnosis of AD there- andhippocampalvolumesby(cid:2)15-25%(Chan fore needs to take into account the overall et al. 2001; Dickerson et al. 2001; Schuff et al. patternofimaging(andother)featuresofthese 2009). Because rates of hippocampal atrophy dementias:forinstance,focalfrontal/temporal inmildADare (cid:2)3-5%peryear(Barnesetal. lobaratrophyonMRIwouldpointtoadiagno- 2009)thissuggeststhattheremusthavebeena sis of FTD, whereas marked signal changes in period of several years before diagnosis where white matter may suggest VaD (Chan et al. medial temporal lobe atrophy was already in 2001; Scheltens et al. 2002; Likeman et al. process.LongitudinalMRIstudiesofindividu- 2005; Rabinovici et al. 2007; Frisoni et al. alswhoareinitiallyasymptomaticbutwhosub- 2010). The overall pattern of atrophy is used sequently develop AD support this suggestion inclinicalpracticeandthereisinterestinauto- andfindthathippocampalvolumesarealready mated pattern classification of MRI to predict reduced byabout 10% 3 yearsbefore receiving ADatanearlystageandtodistinguishitfrom a diagnosis of dementia due to AD and that other dementias (Kloppel et al. 2008; Misra ratesofhippocampalatrophyincreasegradually etal.2009;Vemurietal.2009). some5yearsbeforediagnosis.Bythetimeaclin- icaldiagnosisismade,atrophyisalsoquitewide- MeasuringProgressioninADwith spread with whole brain volumes down by StructuralMRI (cid:2)6%;ratesoflosshavinggraduallyaccelerated (at(cid:2)0.3%/yr2)inthe2-4yearsuptoadiagno- The fact that pathologically increased cerebral sis (Chan et al. 2003; Ridha et al. 2006; Jack atrophystartsearly(evenpresymptomatically), etal.2008b). continues relentlessly,at least until individuals Assessmentofmedialtemporalatrophyon areseverelyaffected,andcorrelateswithclinical MRIhasbeenshowntohavepositivepredictive decline has led to atrophy on MRI being sug- value for AD. Visual assessment differentiates gested as a marker of disease progression and mild AD from normal aging with a sensitivity a potential outcome measure in trials. The and specificity of (cid:2)80-85% (Scheltens et al. amount,distribution,andrateofcerebralatro- 1992; Duara et al. 2008; Burton et al. 2009). phy are all closely correlated with cognitive DifferentiatingMCIsubjectswhowillprogress deficits (Hua et al. 2008; Ridha et al. 2008; to AD in the near future from those who will Cardenas et al. 2009; Fox et al. 1999b). In the not is a more difficult task: Medial temporal absence of an intervention cerebral volume atrophy on MRI is still a very significant pre- lossinADhasclear,direct,andprofoundneg- dictor of progression with sensitivity and ative clinical consequences. Epidemiological- specificityof(cid:2)50-70%fordistinguishingindi- autopsystudiesofindividualswithandwithout vidualswhowillprogresstoADfromthosewho dementia showed that, whereas plaques, tan- willnot (Korfetal.2004;DeCarlietal.2007). gles,andatrophyareallassociatedwithdemen- For these reasons medial temporal lobe atro- tia, atrophy was the factor that most strongly phy now forms one of the biomarkers of AD correlated with dementia at all ages (Savva included in proposed criteria for diagnosing et al. 2009). It appears that histopathological 4 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease hallmarksofADaremarkersofdiseaseprocess min and more basic sequences in considerably whereas the clinical state is captured by the lesstime.MRIissafeandasitdoesnotinvolve extent of neurodegeneration-for which atro- ionizing radiation individuals can be imaged phy may be considered an in vivo measure. seriallywithoutconcernsaboutcarcinogenicity. Rates of regional and/or global atrophy on MRI offers a range of different sequences that MRIhaveasaresultbeenproposedasoutcome canprobedifferenttissuecharacteristicsprovid- measures in trials seeking to show a disease- ing multiple clinical and research measures in modification effect in AD; the motivation for thesamesession.Atrophyasanoutcomemeas- thisisthepotentiallyincreasedpowertodetect urehasstrengthsoverclinicalmeasuresbecauseit a disease-slowing effect. Sample size calcula- isnotsubjecttopracticeeffectsor(realistically)to tions based on natural history studies would floororceilingeffects,andittheoreticallyhasa supportthiswithonly(cid:2)20%asmanypatients greater ability to detect disease slowing. MRI beingexpectedtobeneededforthesameeffect measuresofatrophyreflectcumulativeneuronal usingMRImeasuresthanifclinicalscaleswere damagewhichinturnisdirectlyresponsiblefor used (Fox et al. 2000; Jack et al. 2008a; Ridha clinicalstate.Whencomparedwithotherimag- etal.2008;Schuffetal.2009).Ratesofhippo- ing markers (and other biomarkers) cerebral campal and whole brain atrophyon MRI have atrophyhas,asastrength,itsstrongcorrelation todatebeenthemostwidelyincludedimaging withcognitivedecline. measures in trials; however, other MRI meas- uresshowpromise,includingcorticalthickness LimitationsofStructuralMRIinAD orcompositesofchange(Lerchetal.2005;Hua etal.2008;Jacketal.2008a;Vemurietal.2009). Structural MRI lacks molecular specificity. It Thevalidationofthisapproach,however,awaits cannot directly detect the histopathological the discovery of disease-modifying therapies hallmarks of AD (amyloidplaques or neurofi- particularlyastherapies may have an effect on brillary tangles) and as such it is downstream progression of volume loss through mecha- fromthemolecularpathology.Cerebralatrophy nisms other than reduced rates of neuronal isanonspecificresultofneuronaldamageand, loss (e.g., hydration, inflammatory, and anti- whereascertainpatternsoflossarecharacteristic inflammatory effects) (Fox et al. 2005a). It is of different diseases, they are not entirely spe- likely that multiple imaging and fluid bio- cific. Atrophy patterns overlap with other dis- markers will be included in trials that seek to eases and unusual forms of AD have atypical understandaswellasmeasureeffectsondisease patternsofatrophytoo.Inmoreseverelyaffected progression. individualsandthosewithclaustrophobia,MRI may not be tolerated whereas a rapid CTscan may be more feasible. In terms of measuring AvailabilityandUtilityofStructuralMRI progression, volume changes on MRI may be AnobviousstrengthofMRIisitsavailability.A producedbyfactorsotherthantheprogression testamenttoitsvalueindiagnosisindementia ofneuronallossandassuchassessmentofdis- isthefactthatEuropeanandU.S.guidelinesrec- ease modification may be obscured, at least in ommendthatallsubjectswithcognitivedecline theshortterm,bysuchspuriouseffects.Asthe undergo structural imaging (MRI or CT) and name implies, structural MRI cannot assess that it is part of proposed diagnostic criteria function; this is provided with increasing for AD and for other dementias (Waldemar sophisticationbyfunctionalMRIandPET. et al. 2000; Knopman et al. 2001; McKeith Overalltheavailability,easeofuse,andmul- etal.2005;Duboisetal.2007).Inmostcenters, tipleapplicationsofstructuralMRIinADmean MRIisregardedasanessentialinvestigationin itwillplayacentralroleinresearchandpractice dementia-a marker of its utility. Although forsomeyearstocome.Increasingly,theother not as rapid as CT, a typical high-resolution (complementary) modalities described in this volumetric sequence can be acquired in 5-10 articlewilladdresstheweaknessesofMRI. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 5 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. FUNCTIONALMRIINAD consistent,showingdecreasedhippocampalac- tivityduringtheencodingofnew information BasicsofFunctionalMRIasAppliedtoAD (Small et al. 1999; Rombouts et al. 2000; Kato Functional MRI (fMRI) is being increasingly et al. 2001; Gron et al. 2002; Machulda et al. used to probe the functional integrityof brain 2003; Sperling et al. 2003; Remy et al. 2004; networkssupportingmemoryandothercogni- Golbyetal.2005;Hamalainenetal.2007).Sev- tive domains in aging and early AD. fMRI is eral studies have reported increased prefrontal a noninvasive imaging technique which pro- cortical activity in AD patients (Grady et al. vides an indirect measure of neuronal activity, 2003; Sperling et al. 2003; Sole-Padulles et al. inferred from measuring changes in blood 2009), suggesting that other networks may oxygen level-dependent (BOLD) MR signal increaseactivityasanattemptedcompensatory (Ogawaetal.1990;Kwongetal.1992).Whereas mechanismduringhippocampalfailure. fluoro-deoxy-D-glucose(FDG)-PETisthought A relatively small number of fMRI studies to be primarily a measure of synaptic activity, havebeenpublishedinsubjectsatriskforAD, BOLD fMRI is considered to reflect the inte- including MCI subjects and genetic at-risk gratedsynapticactivityofneuronsviaMRIsig- individualsyieldingsomewhatdiscrepantfind- nal changes because of changes in blood flow, ings. Several studies have reported decreased bloodvolume,andthebloodoxyhemoglobin/ mesial temporal lobe (MTL) activation in deoxyhemoglobinratio(Logothetisetal.2001). MCI (Small et al. 1999; Machulda et al. 2003; fMRI can be acquired during cognitive tasks, Johnson et al. 2006; Petrella et al. 2006) and typicallycomparingonecondition(e.g.,encod- genetic at-risk subjects (Smith et al. 1999; ing new information) to a control condition Lindetal.2006a,b;Trivedietal.2006;Borghe- (e.g., viewing familiar information or visual sani et al. 2007; Mondadori et al. 2007; Ring- fixation on across-hair), orduring the resting man et al. 2010). Interestingly, several fMRI state to investigate the functional connectivity studies have reported evidence of increased (fc-MRI) within specific brain networks. Fc- MTL activity in at-risk subjects, particularly MRI techniques examine the correlation be- among very mild MCI subjects (Dickerson tween the intrinsic oscillations or time course etal.2004,2005;Celoneetal.2006;Hamalainen of BOLD signal between brain regions (Fox etal.2006;Heunetal.2007;Kircheretal.2007; etal.2005b),andhaveclearlydocumentedthe Lenzi et al. 2009), and cognitively intact indi- organization of the brain into multiple large- viduals with genetic risk for AD (Bookheimer scale brain networks (Damoiseaux et al. 2006; et al. 2000; Smith et al. 2002; Wishart et al. Vincent et al. 2006). Both task-related and 2004; Bondi et al. 2005; Fleisher et al. 2005; resting fMRI techniques have the potential to Hanetal.2007;Filippinietal.2009).Itislikely detect early brain dysfunction related to AD, that these discrepant results arerelated to spe- andtomonitortherapeuticresponseoverrela- cific paradigm demands, stage of impairment, tively short time periods; however, the use of and behavioral performance. A common fea- fMRIinaging,MCI,andADpopulationsthus ture of the studies reporting evidence of farhasbeenlimitedtoarelativelysmallnumber increased fMRI activity isthat the at-risk sub- ofresearchgroups. jects were able to perform the fMRI tasks rea- sonably well. In particular, the event-related fMRI studies have found that hyperactivity UtilityofFunctionalMRIintheStudyofAD was observed specifically during successful Much of the early fMRIwork in MCI and AD memorytrials,whichsuggestedthathyperactiv- used episodic memory tasks, and was focused itymightrepresentacompensatorymechanism on the pattern of fMRI activation in hippo- inthesettingofearlyADpathology(Dickerson campus and related structures in the medial andSperling2008;Sperlingetal.2009). temporal lobe. In patients with clinically Cross-sectional studies suggest that the diagnosed AD, the results have been quite hyperactivitymaybepresentonlyatearlystages 6 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease ofMCI,followedbyalossofactivationinlate activityandthe interregional correlationsdur- stages of MCI, similar to the pattern seen in ing the resting state. These studies haveclearly ADpatients(Celoneetal.2006).Longitudinal documentedtheorganizationofthebraininto studies furthermore suggest that the presence multiple large-scale brain networks (Damoi- of hyperactivity at baseline is a predictor seauxetal.2006;Vincentetal.2007).Interest- of rapid cognitive decline (Bookheimer et al. ingly, both independent component analyses 2000; Dickerson et al. 2004; Miller et al. and“seed-based”connectivitytechniqueshave 2008a), and loss of hippocampal function on showntherobustintrinsicconnectivitybetween serial fMRI (O’Brien et al. 2010). The mecha- theposteromedialnodesofthedefaultnetwork, nistic underpinnings of MTL hyperactivation inparticulartheposteriorcingulate/precuneus, remain unclear; however, these new longitudi- with the hippocampus. Multiple groups have nal data suggest that hyperactivity may be a confirmed impaired intrinsic functional con- marker of impending neuronal failure. This nectivityinthedefaultnetworkduringtherest- phenomena may reflect cholinergic or other ing statein MCIandAD(Greicius etal.2004; neurotransmitterup-regulation(DeKoskyetal. Rombouts et al. 2005, 2009; Sorg et al. 2007; 2002), aberrant sprouting of cholinergic fibers Baietal.2008;Kochetal.2010)overandabove (Masliah et al. 2003), inefficiency in synaptic more general age-related disruption of large- transmission (Stern etal. 2004),increased cal- scale networks (Andrews-Hanna et al. 2007; cium influx, and evidence of excitotoxicity Damoiseauxetal.2008).Onerecentstudysug- (Palopetal.2007;Buscheetal.2008). geststhattheserestingfMRItechniquesmaybe Convergingdatasuggestthatmemoryfunc- morereadilyappliedtoat-riskclinicalpopula- tionissubservedbyanetworkofbrainregions, tions than task fMRI (Fleisher et al. 2009). which includes not only the MTL system, but Fc-MRI may be particularly advantageous for alsoasetofcorticalregions,includingthepre- useinclinicaltrials,asnospecialequipmentis cuneus,posteriorcingulate,lateralparietal,lat- required,subjectsdonothavetobeabletoper- eral temporal, and medial prefrontal regions, formacognitivetask,andarestingruncouldbe collectively known as the “default network” addedtotheendofasafetyorvolumetricMRI which typically deactivate during memory protocol.Additionallongitudinalworkisneed- encoding and other cognitively demanding ed to determine if longitudinal changes in fc- tasksfocusedontheprocessingofexternalstim- MRIwillparallelclinicaldecline. uli (Raichle et al. 2001; Buckner et al. 2008). Interestingly, the default network regions Recent studies have also suggested that the showing aberrant task-related fMRI activity default network shows markedly abnormal anddysconnectivityinMCIandADalsoover- responses during memory tasks in clinical AD lap the anatomy of regions with the highest patients and in subjects at risk for AD (Lustig amyloid burden in AD patients (Fig. 2; Klunk and Buckner 2004; Celone et al. 2006; Petrella etal.2004;Buckneretal.2005,2009;Sperling et al. 2007a; Pihlajamaki et al. 2008, 2009). etal.2009).Severalrecentstudiesincognitively Interestingly, it is the same default network normalolderindividualswithevidenceofamy- regionsthattypicallyshow beneficial deactiva- loid deposition on PET imaging have shown tionsinhealthysubjects,particularly,theposte- evidence of disrupted default network activity riorcingulate/precuneus (Daselaaretal.2004; during memory tasks and at rest (Hedden Miller et al. 2008b), which tend to manifest a et al. 2009; Sheline et al. 2009; Sperling et al. paradoxical increase in fMRI activity (or loss 2009),suggestingthesemarkersmaybepartic- of normal default network deactivation) in ularly useful to track response to antiamyloid both at-risk groups and clinical AD patients therapiesinpreclinicaltrials. (Petrella et al. 2007b; Pihlajamaki et al. 2008; fMRI,eitherduringcognitiveparadigmsor Fleisheretal.2009;Sperlingetal.2010). during resting state, may hold the greatest TherehasbeenarecentemphasisonBOLD potentialfortheevaluationofnovelpharmaco- fMRI techniques to study spontaneous brain logicalstrategiestotreatAD.Severalstudiesin CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 7 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. tobevariableacrosssubjects,andveryfewstud- iesexaminingthereproducibilityoffMRIacti- vation in older and cognitively impaired subjectshavebeenpublishedtodate(Clement andBelleville2009;Putchaetal.2010).Longi- tudinal functional imaging studies are needed fMRI activity during PiB-PET memory encoding amyloid imaging to track the evolution of alterations in the fMRI activation pattern over the course of the Figure2.(Left)GroupmapoffMRIactivityshowing cognitive continuum from preclinical to pro- regionsthatincreaseactivity(yellow/red)ordecrease dromal to clinical AD. It is also important (blue) activity during successful encoding. (Right) toevaluatethecontributionofstructuralatro- Groupmapof11C-PiBretentioninagroupofnon- phytochangesobservedwithfunctionalimag- dementedolderindividuals.Notetheanatomicover- ing techniques in neurodegenerative diseases. lap of PiB retention to default network (regions in blueonleft). Finally, longitudinal multimodality studies, includingstructuralMRI,fMRI,andFDG-PET and PET amyloid imaging techniques, are healthy young and older subjects suggest that neededtounderstandtherelationshipbetween fMRI can detect acute pharmacological effects these markers, and the relative value of these onmemorynetworks(Thieletal.2001;Sperl- techniquesintrackingchangealongtheclinical ing et al. 2002; Kukolja et al. 2009). To date, continuumofAD(Jacketal.2010). only a few small fMRI studies have shown enhanced brain activation after acute or pro- longedtreatmentwithcholinesteraseinhibitors FLUORODEOXYGLUCOSE(FDG)PETINAD inMCIandAD,althoughthesestudieswerenot conducted as typical double-blind, placebo- BasicsofFDGPETasAppliedtoAD controlled trials (Rombouts et al. 2002; Goe- Brain FDG PET primarily indicates synaptic koop et al. 2004; Saykin et al. 2004; Shanks activity. Because the brain relies almost exclu- et al. 2007; Bokde et al. 2009; Venneri et al. sively on glucose as its source of energy, the 2009). fMRI is now being incorporated into a glucose analog FDG is a suitable indicator of small number of investigator-initiated add-on brainmetabolismand,whenlabeledwithFluo- studiestoongoingPhaseIIandPhaseIIItrials, rine-18 (half-life 110min) is conveniently de- which should provide some valuable informa- tected with PET. The brain’s energy budget is tionregardingthepotentialutilityofthesetech- overwhelmingly devoted to the maintenance niquesinclinicaltrials. ofintrinsic,resting(task-independent)activity, which in cortex is largely maintained by glu- LimitationsoffMRIinAD tamaturgic synaptic signaling (Sibson et al. There are multiple challenges in performing 1997).FDGuptakestronglycorrelatesatauto- longitudinal fMRI studies in patients with psy with levels of the synaptic vesicle protein neurodegenerative dementias. It is likely that synaptophysin (Rocher et al. 2003). Hence, fMRIwillremainquiteproblematicinexamin- FDG PETis widelyacceptedto beavalid bio- ingpatientswithmoreseverecognitiveimpair- marker of overall brain metabolism to which ment, as these techniques are very sensitive to ionicgradientmaintenanceforsynapticactivity head motion. If the patients are not able to is the principal contributor (Schwartz et al. adequately perform the cognitive task, one of 1979;Magistretti2006).Inthiscontext,asingle, the major advantages of task fMRI activation specificAD-relatedalterationinFDGmetabo- studiesislost.RestingstatefMRImaybemore lism has not been identified and therefore the feasibleinmoreseverelyimpairedpatients. FDG-PET abnormalities described below are It is critical to complete further validation assumed to be the net result of some combi- experiments. BOLD fMRI response is known nation of processes putatively involved in the 8 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease pathogenesis of ADincluding,butnotlimited advanced disease usually involves prefrontal to, expression of specific genes, mitochondrial association areas, and in due course even pri- dysfunction, oxidative stress, deranged plasti- mary cortices may be affected. Interestingly, city, excitotoxicity,glial activation and inflam- the regions initially hypometabolic in AD are mation,synapseloss,andcelldeath. anatomically and functionally interconnected and form part of the large-scale distributed brainnetworkknownasthedefaultmodenet- UtilityofFDGPETintheStudyofAD work (Raichle et al. 2001). We now know in addition that these regions are highly vulnera- ThePatternofFDGHypometabolism bletoamyloid-b(Ab)deposition(Klunketal. IsanEndophenotypeofAD 2004;Buckneretal.2005). Asubstantialbodyofworkovermanyyearshas Less severe or consistent hypometabolism identified a FDG-PETendophenotype of AD has been identified in MCI patients, some of (Fig. 3)-that is, a characteristic or signature whom were found on follow-up examination ensemble of limbic and association regions to have converted to AD (Arnaiz et al. 2001; that are typically hypometabolic in clinically deLeonetal.2001;Jagustetal.2002,2007;Che- established AD patients (Foster et al. 1983; telat et al. 2003; Caselli et al. 2008; Langbaum Reimanetal.1996;Minoshimaetal.1997;De et al. 2009; Landau et al. 2010). Differences Santietal.2001).TheanatomyoftheADsigna- in FDG between MCI and normal aging have ture includes posterior midline cortices of the nottypicallybeenlarge,butthecontrolgroups parietal (precuneus) and posterior cingulate in most of these studies were likely contami- gyri, the inferior parietal lobule, posterolateral nated with a number of individuals who, portions of the temporal lobe, as well as the althoughclinicallynormal,wereamyloidposi- hippocampus and medial temporal cortices. tive (see below) and possibly in earlier phases Metabolic deficits in AD gradually worsen ofpreclinicalAD.FDGhypometabolismparal- throughout the course of the disease. Bilateral lels cognitive function along the trajectory of asymmetry is common at early stages, more normal,preclinical,prodromal,andestablished AD(Minoshimaetal.1997;Furstetal.2010); however, higher levels of brain and cognitive reservearewellknowntoattenuatethestrength of these correlations andhighly intelligent AD patients can be clinically mild, but severely Normal hypometabolic (Stern et al. 1992; Alexander et al. 1997). Coexisting vascular disorders, in- cluding ischemia, amyloid angiopathy, and micro-hemorrhage, potentially confound the relation of FDG to clinical phenotype, but the Alzheimer classic AD FDG pattern is well correlated with disease histopathologic diagnosis of AD at autopsy (Hoffmanetal.2000;Jagustetal.2007). Figure 3. Transaxial FDG-PET images of a normal control subject and a patient with mild AD. Note FDGHypometabolismIsRelatedtoOther severe hypometabolism (yellow and blue cortical ADBiomarkersandtoGenes regions)inassociation andlimbiccortex.Theseare the typically involved brain regions that define the The association between amyloid deposition FDGendophenotypeofAD.Theyincludeposterio- and brain function in AD has been studied medial parietal (precuneus), lateral parietal, lateral with FDG PET. Longitudinal data has shown temporal, and medial temporal lobes. This pattern slowlyworsensinparallelwithsymptomsandiswell that,oncethestageofestablishedADisreach- correlatedatautopsywithADpathologicdiagnosis. ed, amyloid deposition in most regions has CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 9 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. plateaued(Engleretal.2006;Jacketal.2009), technology. For example, recently developed butFDGcontinuestodeclinealongwithcogni- methodsforsubject-specificMRIsegmentation tivefunction(Engleretal.2006).Severalgroups haverevealedsubtlecorticalthinninginadistri- haveobservedhighamyloiddepositioninpari- butionsimilartothatseenwithFDG(Walhovd etal regions to be associated with co-localized et al. 2009; Karow et al. 2010). A continuing FDG hypometabolism, possibly indicating a challenge is presented by the fact that FDG- local toxicity (Klunk et al. 2004; Engler et al. PETdatainherentlycontainsvolumeinforma- 2006; Edison et al. 2007; Cohen et al. 2009). tion,andPET-basedpartialvolumecorrection Inothergroups,thisassociationwasnotstatisti- (e.g., with deconvolution [Tohka and Reilhac cally significant, possibly because the amyloid 2008]),mayeventuallybeusefultodisentangle burdenin thesepatientswasalreadyatitspla- FDGretentionandstructuralloss. teau (Kadir et al. 2008; Furst et al. 2010). An Initial reports associating FDG hypome- importantcluetothisrelationshipcouldliein tabolism and AD-related CSF measures have theobservationthattherelationisconsistently varied,likelydueinparttoimageandfluidsam- weaker in frontal regions, where some of the ple processing differences. FDG was associated highest amyloid burdens are found (Klunk withlowCSFAbandincreasedCSFtauinamy- et al. 2004; Edison et al. 2007). Interestingly, loid-positiveclinicallynormalolderindividuals amyloid-positive MCI patients in one study (Petrieetal.2009),butwithCSFAbandnottau had preserved FDG metabolism that was pos- inanAlzheimer’sDiseaseNeuroimagingInitia- itively correlated with extensive Pittsburgh tive (ADNI) study of AD, MCI, and controls, Compound-B(PiB)retention,possiblysuggest- adjustedfordiagnosis(Jagustetal.2009). ing a mediating role for metabolism, perhaps Carriersoftheapolipoprotein-E(APOE)14 eitherasabrainreservefactororasanaccelerant allelehaveahigherriskofdevelopingAD,and of deposition (Cohen et al. 2009). Additional the classic AD pattern of hypometabolism longitudinal data will be required to clarify described above is seen in cognitively normal theserelationships,butclearlyFDGmetabolism APOE14 carriers (Reiman et al. 1996, 2005). appearstobechangingasamyloidisaccumulat- A relationship of this FDG pattern to serum ing.ItispossiblethatFDGdatacouldsignalan cholesterol and to an aggregate cholesterol- intermediatestagebetweentheinitiatingpatho- related genetic score in middle age has also logiceventandthesubsequentdevelopmentof been reported (Reiman et al. 2008, 2010). synapticfailureandneurodegeneration(Cohen Maternal history of dementia has recently etal.2009). been related both to increased PiB retention Brain volume loss is also observed in AD and to FDG hypometabolism in AD-related hypometabolic areas, but the FDG findings areas among asymptomatic individuals (Mos- havegenerallysurvivedMRI-basedcorrections conietal.2009,2010). forcorticalatrophy(Meltzeretal.1996;Ibanez etal.1998;Jagustetal.2006;Cohenetal.2009; FDGPETIsaValidADBiomarker Lowe et al. 2009; Rabinovici et al. 2010), sug- gesting that volume loss and function loss are Over the course of three decades of inves- separable phenomena in AD. Both domains tigation, FDG PET has emerged as a robust of data are reported to have predictive power: markerofbraindysfunctioninAD.Itsprincipal FDG hypometabolism that predicts ultimate value is twofold: first, clinical utility has been development of AD occurs before impairment documented when confounding conditions (deLeonetal.2001;Jagustetal.2006)andbrain (e.g., DLB or frontotemporal lobar degenera- volume loss has also been reported in cogni- tion [FTLD]), are in question. Thus, when tivelynormalindividualswhogoontodevelop frontotemporal rather than temporoparietal AD(Foxetal.1999a;Jacketal.2004).System- hypometabolism is prominent, a clinically atic comparison of two imaging biomarkers uncertain AD diagnosis may be changed to requires caution because of rapidly evolving FTLD (Foster et al. 2007); when prominent 10 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease occipitalhypometabolismisfoundinaddition surrogate for Ab pathology, and not necessar- totemporoparietal,thedataarehighlysugges- ilyasa surrogateforclinical diagnosis. Asdis- tive of DLB (Albin et al. 1996; Mosconi et al. cussed below,thereare diagnostic applications 2008). of amyloid imaging, but these share the same Second,FDGhasemergedasarobustbio- strengthsandlimitationsaspostmortemdeter- markerofneurodegenerationwithwhichhypo- minations of Ab content. Another important metabolism can be observed to precede the principle of amyloid imaging is that the sub- appearanceofcognitivesymptomsandtopre- strate for all currently known Ab tracers is dicttherateofprogressivecognitivedeclinein fibrillarAbinabeta-sheetconformation(Iko- individuals who are later found to have pro- nomovic et al. 2008). When speaking of the gressed to AD (de Leon et al. 2001; Jagust bindingsubstratesofamyloidtracers,itispref- etal.2006). FDGhypometabolism is alsopre- erable to think in terms of fibrillarand nonfi- dictiveoftherateofmemorydeclineinAPOE brillar Ab rather than visual descriptions of 14carrierswithmildmemorylossover2years plaquesasfleecy,amorphous,diffuse,compact, (Small et al. 2000). Most importantly for AD cored,neuritic,etc.,becausetherecanbevary- treatment research, a recent analysis of ADNI ingamountsoffibrillarAbinanyofthesepla- FDG data found that AD and MCI groups quetypes.Compact,cored,andneuriticplaques each showed progression of AD-like hypome- typicallyhavelargeamountsoffibrillaramyloid tabolism over 1 year that paralleled changes and fleecy and amorphous plaque deposits in a standard clinical endpoint, the clinical typicallyhaveverylittle(particularlyinthecer- dementia rating scale (CDR) sum-of-boxes ebellum). However, diffuse plaques are not a (Chen et al. 2010). These authors calculated precisely defined term and can have widely that the use of FDG PET in clinical trials of varying amounts of fibrillar Ab from case to AD therapy could reduce sample sizes by case.Alongsimilarlines,cerebrovascularamy- approximatelyoneorderofmagnitude. loid typically has a high degree of fibrillar Ab andappearstobeaverygoodsubstrateforamy- loidtracerbinding(Bacskaietal.2007;Johnson TheLimitationsofFDGPETinAD et al. 2007; Lockhart et al. 2007; Ikonomovic FDG PET is relatively expensive and, like all et al. 2008). Increasing recognition has been PET techniques, has more limited availability, given to the toxicity of oligomeric species of although its use in oncology has dramatically AbandthisisdescribedinMuckeandSelkow increased availability in the USA over the past (2011). Although it is possible that currently decade. It requires intravenous access and in- availableamyloidtracerscouldbindtooligom- volves exposure to radioactivity, although at ers of Ab in a beta-sheet conformation once levels well below significant known risk. Brain they reach a necessarysize (probablyat least a FDG retention is a nonspecific indicator of trimeror tetramer), the invivo signal of amy- metabolism that can be deranged foravariety loidtracersisnotdirectlyrepresentativeofthese of reasons (e.g., ischemia or inflammation) speciesbecauseoftheirlowconcentrationrela- and may in certain individuals be irrelevant tivetoinsolubleAbfibrils.However,theremay or only indirectly related to any AD-related be a relationship between the amyloid PET process. signal and oligomer concentration based on theexistenceofanequilibriumbetweenmono- mers, oligomers, and fibrillar Ab. Although AMYLOIDPETINAD claims have been made that some tracers can image neurofibrillary tangles, there have been BasicsofAmyloidPETasItIsAppliedtoAD novalidationstudiesinthisregard.Tothecon- Animportant“firstprinciple”ofamyloidimag- trary,thereisevidencethatsomeamyloidtrac- ing in the context of AD is that amyloid PET ersdonotbindneurofibrillarypathology(Klunk is intended first and foremost as an in vivo etal.2003;Ikonomovicetal.2008). CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 11 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. With regard to specific amyloid imaging as in apparently pure cases of tauopathy in agents,thisreviewwilldiscuss“amyloidtracers” semanticdementia(Drzezgaetal.2008). in general, while acknowledging that most of Inthesettingofclinicaldementia,particu- the statements are derived from data on the larly in clinically atypical presentations, this most widely evaluated PET tracer, PiB (Klunk has important diagnostic utility. Reviewing et al. 2004). At the time of writing, there have recent publications from 15 research groups been one or two, small published studies whohaveperformedamyloidPETonclinically using each of the fluorine-18-labelled tracers, diagnosed AD patients, 96% of AD patients [F-18]florbetaben (18F-BAY94-9172 or AV-1; were amyloid positive (Fig. 4; Kemppainen Rowe et al. 2008), [F-18]florbetapir (AV-45; etal.2006;Aizensteinetal.2008;Edisonetal. Wongetal.2010;Clarketal.2011)and[F-18]flu- 2008;Shinetal.2008;Drzezgaetal.2009;Hed- temetamol (30F-PiB or GE-067; Nelissen et al. denetal.2009;Loweetal.2009;Maetzleretal. 2009;Vandenbergheetal.2010)inADpatients. 2009; Wolk et al. 2009; Devanand et al. 2010; Although the PiB PET findings may ultimately Forsbergetal.2010;Jagustetal.2010;Rabino- befoundtoextendtotheseF-18-labeledtracers vicietal.2010;Roeetal.2010;Roweetal.2010; aswell,thiscannotbeassumeduntilappropriate Tolboom et al. 2010). One assumption is that studieshavebeenrepeatedwitheachindividual amyloid-negativedementedpatientsdiagnosed tracer or until pharmacological equivalency to as AD have been given an incorrect diagnosis. PiB has been established by direct comparison Another possibility is that amyloid imaging inthesamesubjects. was simply not sensitive enough in some patientsandthesepatientswouldbecomeamy- loidpositiveovertime.Onefollow-upofthree UtilityofAmyloidPETintheStudyofAD amyloid-negative subjects initially diagnosed The obvious strength of amyloid imaging is as AD (Klunk et al. 2004), has shown that all that it has allowed the determination of brain three subjects have remained amyloid negative Ab content to be moved from the pathology for 5 years (Kadir et al. 2010), suggesting that laboratory into the clinic. Amyloid imaging sensitivity was not the issue and that these can detect cerebral b-amyloidosis and appears patients are not likely to have AD asthe cause specific for this type of amyloid pathology, oftheircognitivedeficits.Ontheothersideof giving negative signals in pathologically con- the coin are amyloid-positive patients who firmed cases of prion amyloid (Villemagne have been diagnosed with a dementia other et al. 2009), pathologically confirmed pure than AD. In the case of FTD, it has been a-synucleinopathy(Buracketal.2010),aswell assumed that patients who present with a Logan DVR 2.0 1.0 NC- NC+ MCI- MCI+ MCI++ AD Figure4.PiBPETImagesofnormalcontrol,MCI,andADsubjectsshowingarangeofamyloid-bdeposition. Mostcontrolsshownoevidenceofamyloid-bdeposition(NC2),butasubstantialportion((cid:2)25%)do(NCþ). MostpatientswithMCIshowmoderate(MCIþ)orsevereamyloid-bdeposition(MCIþþ),butasmanyas 40%-50%shownoevidenceofamyloid-bpathology(MCI2).ThevastmajorityofclinicallydiagnosedAD patientsshowheavyamyloid-bdeposition(AD). 12 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease clinical FTD syndrome buthaveAD-like amy- et al. 2010; Rowe et al. 2010). Although some loidPETscansarereallyatypicalpresentations subtlecognitiveeffectsofPETamyloidpositiv- of AD (Rabinovici et al. 2007, 2008; Engler itymaybediscernableinthispopulation(Rentz et al. 2008), but pathological verification re- etal.2010),inmostcasestheoverridingconclu- mainstobedone.Thesepatientswillbepartic- sionisthatthereisnotight,directrelationship ularly important to identify when there are between amyloid PET and cognition at these effective treatments for AD directed at Ab earliest stages of Ab deposition. As discussed deposition. above, other protective or vulnerability factors InthesettingofMCI,combineddatafrom mustbeinvokedtofullyexplaintheconnection nine amyloid PET studies show that 161 of betweenearlyPETamyloidpositivityandcog- 272 MCI patients were amyloid positive nitiveimpairment.Itispossiblethatthefailure (59%) (Fig. 4; Forsberg et al. 2008; Koivunen to directly assess oligomeric Ab concentration etal.2008;Loweetal.2009;Okelloetal.2009; could preclude the demonstration of amyloid Tolboometal.2009;Wolketal.2009;Devanand PET-related cognitive effects, but vulnerability etal.2010;Jagustetal.2010;Roweetal.2010). factors(suchassubclinicalcerebrovasculardis- Fiveofthesestudiesincludedlongitudinalclin- ease) and brain/cognitive reserve factors are ical follow-up for 1-3 years on 155 MCI likely to playa role as well (Kemppainen et al. patients and showed that 57 of these 155 pro- 2008; Roeetal.2008,2010;Cohenetal.2009; gressed to clinical AD (37%) and 53 of these Rentzetal.2010). 57 were amyloid positive at baseline (93%); In Blennow et al. (2011), CSF biomarkers onlyfourof54amyloid-negativeMCIpatients are discussed. There is clearly a large overlap progressed to clinical AD in these studies intheinformationavailablefromCSFAb42lev- (7%) (Forsberg et al. 2008; Koivunen et al. elsandamyloidPET,buteachtechniquehasits 2008;Okelloetal.2009;Wolketal.2009;Jagust advantages and limitations (see below). The etal.2010). advantages of amyloid PET center around the Themostsubstantialcontribution ofamy- regional information and in the continuously loidimagingmaycomeinthesettingofthecog- variable nature of the biological changes. The nitively normal elderly. It is at this clinically latter refers to the fact that decreases in CSF “invisible” stage that detection of underlying Ab42appeartooccurearly(atleastasearlyas cerebral b-amyloidosis (the sine qua non of changes in amyloid PET) and precipitously- ADpathology)maygiveusthegreatestinsights achievingitsfinallevelveryearlyinthecourse intotheverybeginningsofthisdisease.Further- of the pathophysiological spectrum of AD- more,itmaybeatthisasymptomaticstagethat probably presymptomatically (Blennow and our chances are greatest of discovering truly Hampel 2003; Hansson et al. 2006; Fagan effectivetreatments.Inaseriesofstudiesfrom et al. 2007, 2009). That is, the change in CSF 13sites,155of651(24%)ofcognitivelynormal appearstobeastep-functionandlongitudinal controlsshowedevidenceofcerebralAbdepo- studies have not shown a progressive decrease sition(Fig.4;Kemppainenetal.2006;Mintun inCSFAb42overtime(Buchhaveetal.2009). etal.2006;Edisonetal.2008;Shinetal.2008; Thisisnotsurprisinggiventhattypicalconcen- Heddenetal.2009;Loweetal. 2009;Maetzler trations of Ab found in insoluble deposits et al. 2009; Wolk et al. 2009; Devanand et al. in AD cortex are approximately 5000mg/L 2010;Jagustetal.2010;Rabinovicietal.2010; ((cid:2)1mM), while typical CSF Ab42 concen- Roe et al. 2010; Rowe et al. 2010; Tolboom trations are around 0.5mg/L-or 0.01% of etal.2010).Inmostcases,thedegreeofamyloid insolublecorticalAb.Thus,itisnotsurprising deposition was fairly easy to distinguish from that relatively little cortical Ab would need to that typically seen in AD (Aizenstein et al. deposit before a new equilibrium would be 2008),butthisisnotalwaysthecase.Theprev- established with CSF. This has an important alenceofamyloidpositivityisrelatedcloselyto implication for clinical trials: As an outcome age and apolipoprotein-E allele status (Morris measure, CSFAb42 is not likely to normalize CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 13 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. until the vast majority of cortical Ab deposits pathology of AD, but when that pathology is are removed. Thus, CSF Ab42 and amyloid absent, a negative amyloid PET scan will be PETarelikelytobeequivalentasscreeningtools identical regardless of the non-AD etiology of forclinicaltrials,butthemoredynamicnature the dementia. In contrast, MRI and FDG PET ofamyloidPETandthefactthatamyloidtracer may give an indication of afrontotemporal or retentioncorrelatesdirectlywithAbload(Iko- vascular pathology when an amyloid PET nomovicetal.2008)makesthisamoresuitable scan would be ambiguously negative in both outcome measure when the goal is to detect cases. The threshold of sensitivity of amyloid changes in brain Ab load. In support of this PET has yet to be precisely determined, but it statement, the abilityof amyloid PET to show is clear that some level of amyloid deposition anamyloid-loweringeffectofpassiveimmuno- is histologically detectable prior to the in vivo therapy in humans has already been reported signalbecoming“positive”(Cairnsetal.2009). (Rinneetal.2010). AuniquestrengthofamyloidPETacrossthe entireclinicalspectrumistheregionallyspecific SUMMARY nature of the quantitative data. Although we State-of-the-(Imaging)-Art often reduce imaging data to a single number (e.g.,meancorticalretention),wemustremem- In this chapter we briefly reviewed the most ber that a strength of any imaging technique commonly used imaging technologies: struc- is the wealth of regional information that is turalandfunctionalMRIandFDGandamyloid supplied. Although amyloid PET can quantify PET. Other MRI techniques such as diffusion amyloid load throughout the brain, it is not tensorimaging(DTI)andassociatedtractogra- clear what pool of brain Ab is represented by phy technologies, arterial spin labeling meas- changes in CSF Ab. One study has suggested ures of cerebral blood flow and PET tracers thatCSFAbismosttightlycorrelatedwithamy- targeted at the cholinergic system, microglial loidretentioninbrainregionsadjacenttoCSF activation and other tracers in development spaces(Grimmeretal.2009). arealso contributing to our basic understand- ing of AD. A particularly exciting pursuit is PET ligands targeting the other major TheLimitationsofAmyloidPETinAD AD pathologic hallmark, the neurofibrillary Majordeterrentstothewidespreaduseofamy- tangle.Biomarkersoftauhavebeenaparticular loidPETremaincostandavailability.Availabil- challengebecauseoftheneedtotargetbinding ity has been improved by the development of to something other than the b-sheet fibril F-18-labeled agents that can be distributed to dominated by Ab deposits and the relatively PETscanners not associated with a cyclotron. smaller total mass of tau deposits, but steady Cost remains an issue, especially where CSF progress is being made to achieve sufficient measurementofAb42canprovideverysimilar ligandaffinityandselectivity.Itshouldbeclear information when the question is simply the from the above discussions that no single presence or absence of brain Ab deposition. imaging technique can provide all of the Being an early event in the pathogenesis of answers. Fortunately, the strengths and weak- AD, amyloid PET is not a good surrogate ness of the available imaging technologies are markerofprogressionduringtheclinicalstage largelycomplementary.Thishasledtoavariety of the disease (Engler et al. 2006; Kadir et al. of“multi-modal”imagingstudiesinwhichsev- 2010). This role is filled much better bystruc- eral techniques are simultaneously or sequen- tural MRI and FDG PET (Jack et al. 2010). tiallyappliedtothesamesubjectsforthesame Similarly, amyloid imaging gives much more period oftime.Thesedirectcomparisonshave of a binary diagnostic readout than tech- contributed greatly to our understanding of niquessuchasMRIandFDGPET.Thatis,amy- AD and the strengths and limitations of each loid imaging has a certain specificity for the technique. 14 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease LookingtotheFuture:TheRoleofImagingin REFERENCES theTreatmentofAD (cid:2) Referenceisalsointhiscollection. The search for therapies that can modify the AizensteinHJ,NebesRD,SaxtonJA,PriceJC,MathisCA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck courseofAD-toslow,delay,orpreventit-is PR,etal.2008.Frequentamyloiddepositionwithoutsig- clearly our most important challenge. That nificant cognitive impairment amongthe elderly. Arch search has in turn led to a search for imaging Neurol65:1509-1517. markersthat can be used as outcomes in drug AlbinRL,MinoshimaS,D’AmatoCJ,FreyKA,KuhlDA, discoveryand trials. The value of any imaging SimaAA.1996.Fluoro-deoxyglucosepositronemission tomography in diffuse Lewy body disease. Neurology technology will ultimately be determined by 47:462-466. its contribution to meeting the challenge of AlexanderGE,FureyML,GradyCL,PietriniP,BradyDR, findingandusingeffectivetherapies.Thisvalue MentisMJ,SchapiroMB.1997.Associationofpremor- includes contributions toward diagnosis. The bidintellectualfunctionwithcerebralmetabolisminAlz- heimer’sdisease:Implicationsfor thecognitivereserve large variability, intrinsic to clinical outcomes hypothesis.AmJPsychiatry154:165-172. inAD,meansthatstudiesrelyingpurelyonclin- Andrews-HannaJR,SnyderAZ,VincentJL,LustigC,Head ical measures are necessarily large and conse- D,RaichleME,BucknerRL.2007.Disruptionoflarge- quentlyverycostly.Usingclinicaloutcomesto scale brain systems in advanced aging. Neuron 56: 924-935. power studies to establish meaningful disease- Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, slowingeffectsmayrequirecomplicateddesigns ValindS,NordbergA.2001.Impairedcerebralglucose andthousandsofsubjects.Amajoraiminaca- metabolismandcognitivefunctioningpredictdeteriora- demiaandindustryhasbeentofindbiomarkers tion in mild cognitive impairment. Neuroreport 12: 851-855. that could identify disease-slowing effects ear- BacskaiBJ,FroschMP,FreemanSH,RaymondSB,Augusti- lier and/or with significantly fewer subjects nackJC,JohnsonKA,IrizarryMC,KlunkWE,Mathis exposedtotreatment.Imagingisbeingincreas- CA, Dekosky ST, et al. 2007. Molecular imaging with inglyincorporatedintotrialdesignstomeasure PittsburghCompoundBconfirmedatautopsy:Acase report.ArchNeurol64:431-434. the effects of a therapy on fibrillary amyloid BaiF,ZhangZ,YuH,ShiY,YuanY,ZhuW,ZhangX,QianY. (with amyloid imaging) on atrophy (with 2008. Default-mode network activity distinguishes MRI)andonmetabolism(PETandfMRI). amnestictypemildcognitiveimpairmentfromhealthy Asincreasinglybiologicallyactivetherapies aging:Acombinedstructuralandresting-statefunctional MRIstudy.NeurosciLett438:111-115. are studied, so too have side effects increased. BarberR,BallardC,McKeithIG,GholkarA,O’BrienJT. Imaging is emerging as a means of detecting 2000. MRI volumetric study of dementia with Lewy potential adverse effects that can initially be bodies:AcomparisonwithADandvasculardementia. clinically silent or go unrecognized because of Neurology54:1304-1309. a patient’s level of cognitive impairment and BarnesJ,BartlettJW,vandePolLA,LoyCT,ScahillRI,Frost C,ThompsonP,FoxNC.2009.Ameta-analysisofhippo- confusion (Salloway et al. 2009). Particularly campalatrophy rates in Alzheimer’s disease. Neurobiol withmorebiologicallyactivetherapies,regular Aging30:1711-1723. monitoring, or so-called safety scans, are now Blennow K, Hampel H. 2003. CSF markers for incipient aprerequisiteinsuchtrials. Alzheimer’sdisease.LancetNeurol2:605-613. Therecognitionthatitmaybenecessaryto (cid:2) Blennow K, Zetterberg H, Fagan AM. 2011. Fluid bio- markersinAlzheimerdisease.ColdSpringHarbPerspect intervene at a very early stage to effect disease Meddoi:10.1101/cshperspect.a006221. modificationhasledtointerestin“prevention” BobinskiM,deLeonMJ,WegielJ,DesantiS,ConvitA,Saint studies.Preclinicalinterventionstudies,almost Louis LA, Rusinek H, Wisniewski HM. 2000. The bydefinition, are difficult to poweron clinical histological validation of post mortem magnetic reso- nance imaging-determined hippocampal volume in outcomes. Imaging and other biomarkers are Alzheimer’sdisease.Neuroscience95:721-725. likely to be needed to select subjects for these BokdeAL,KarmannM,TeipelSJ,BornC,LiebM,Reiser studies and to provide outcome measuresthat MF,MollerHJ,HampelH.2009.Decreasedactivation can assess whether therapies are having a alongthedorsalvisualpathwayaftera3-monthtreat- ment with galantamine in mild Alzheimer disease: disease-modifying effect that could potentially Afunctionalmagneticresonanceimagingstudy.JClin translateintoadelayinclinicalonset. Psychopharmacol29:147-156. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 15 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. BondiMW,HoustonWS,EylerLT,BrownGG.2005.fMRI memory decline in subsequent converters to amnestic evidenceofcompensatorymechanismsinolderadultsat pre-mildcognitiveimpairment.ArchNeurol65:1231- geneticriskforAlzheimerdisease.Neurology64:501- 1236. 508. CeloneKA,CalhounVD,DickersonBC,AtriA,ChuaEF, BookheimerSY,StrojwasMH,CohenMS,SaundersAM, MillerSL,DePeauK,RentzDM,SelkoeDJ,BlackerD, Pericak-VanceMA,MazziottaJC,SmallGW.2000.Pat- etal.2006.Alterationsinmemorynetworksinmildcog- ternsofbrainactivationinpeopleatriskforAlzheimer’s nitiveimpairmentandAlzheimer’sdisease:Anindepend- disease.NewEnglJMed343:450-456. entcomponentanalysis.JNeurosci26:10222-10231. BorghesaniPR,JohnsonLC,SheltonAL,PeskindER,Ayl- Chan D, Fox NC, Scahill RI, Crum WR, Whitwell JL, wardEH,SchellenbergGD,CherrierMM.2007.Altered LeschzinerG,RossorAM,StevensJM,CipolottiL,Ros- medial temporal lobe responses during visuospatial sor MN. 2001. Patterns of temporal lobe atrophy in encoding in healthy APOE(cid:2)4 carriers. Neurobiol Aging semanticdementiaandAlzheimer’sdisease.AnnNeurol 29:981-991. 49:433-442. BraakH,BraakE.1991.NeuropathologicalstagingofAlz- ChanD,JanssenJC,WhitwellJL,WattHC,JenkinsR,Frost heimer-related changes. Acta Neuropathol (Berl) 82: C,RossorMN,FoxNC.2003.Changeinratesofcerebral 239-259. atrophy over time in early-onset Alzheimer’s disease: BuchhaveP,BlennowK,ZetterbergH,StomrudE,Londos LongitudinalMRIstudy.Lancet362:1121-1122. E,AndreasenN,MinthonL,HanssonO.2009.Longitu- ChenK,LangbaumJB,FleisherAS,AyutyanontN,Reschke dinal study of CSF biomarkers in patients with Alz- C,LeeW,LiuX,BandyD,AlexanderGE,ThompsonPM, heimer’sdisease.PLoSOne4:e6294. etal.2010.Twelve-monthmetabolicdeclinesinprobable BucknerRL,SnyderAZ,ShannonBJ,LaRossaG,SachsR, Alzheimer’sdiseaseandamnesticmildcognitiveimpair- FotenosAF,ShelineYI,KlunkWE,MathisCA,Morris mentassessedusinganempiricallypre-definedstatistical JC, et al. 2005. Molecular, structural, and functional region-of-interest:FindingsfromtheAlzheimer’sDisease characterization of Alzheimer’s disease: Evidence for NeuroimagingInitiative.Neuroimage51:654-664. a relationship between default activity, amyloid, and ChetelatG,DesgrangesB,delaSayetteV,ViaderF,Eustache memory.JNeurosci25:7709-7717. F, Baron JC. 2003. Mild cognitive impairment: Can BucknerRL,Andrews-HannaJR,SchacterDL.2008.The FDG-PET predict who is to rapidly convert to Alz- brain’s default network: Anatomy, function, and rele- heimer’sdisease?Neurology60:1374-1377. vancetodisease.AnnNYAcadSci1124:1-38. ClarkCM,SchneiderJA,BedellBJ,BeachTG,BilkerWB, Buckner RL, Sepulcre J, TalukdarT, KrienenFM, Liu H, MintunMA,PontecorvoMJ,HeftiF,CarpenterAP,Flit- Hedden T, Andrews-Hanna JR, Sperling RA, Johnson terML,etal.2011.AV45-A07StudyGroup.Useofflor- KA.2009.Corticalhubsrevealedbyintrinsicfunctional betapir-PET for imaging b-amyloid pathology. J Am connectivity:Mapping,assessmentofstability,andrela- MedAssoc305:275-283.Erratumin:JAmMedAssoc tiontoAlzheimer’sdisease.JNeurosci29:1860-1873. 305:1096. BurackMA,HartleinJ,FloresHP,Taylor-ReinwaldL,Perl- ClementF,BellevilleS.2009.Test-retestreliabilityoffMRI mutterJS,CairnsNJ.2010.Invivoamyloidimagingin verbal episodic memory paradigms in healthy older autopsy-confirmed Parkinson disease with dementia. adultsandinpersonswithmildcognitiveimpairment. Neurology74:77-84. HumBrainMapp30:4033-4047. Burton EJ, Barber R, Mukaetova-LadinskaEB, Robson J, CohenAD,PriceJC,WeissfeldLA,JamesJ,RosarioBL,BiW, PerryRH,JarosE,KalariaRN,O’BrienJT.2009.Medial Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, et al. temporallobeatrophyonMRIdifferentiatesAlzheimer’s 2009.Basalcerebralmetabolismmaymodulatethecog- disease from dementiawith Lewy bodies and vascular nitive effects of Ab in mild cognitive impairment: An cognitiveimpairment:Aprospectivestudywithpatho- exampleofbrainreserve.JNeurosci29:14770-14778. logicalverificationofdiagnosis.Brain132:195-203. DamoiseauxJS,RomboutsSA,BarkhofF,ScheltensP,Stam Busche MA, Eichhoff G, Adelsberger H, Abramowski D, CJ,SmithSM,BeckmannCF.2006.Consistentresting- WiederholdKH,HaassC,StaufenbielM,KonnerthA, state networks across healthy subjects. Proc Natl Acad Garaschuk O. 2008. Clusters of hyperactive neurons Sci103:13848-13853. nearamyloidplaquesinamousemodelofAlzheimer’s DamoiseauxJS,BeckmannCF,ArigitaEJ,BarkhofF,Schel- disease.Science321:1686-1689. tensP,StamCJ,SmithSM,RomboutsSA.2008.Reduced CairnsNJ,IkonomovicMD,BenzingerT,StorandtM,Fagan resting-state brain activity in the “default network” in AM,ShahA,SchmidtRE,PerryA,ReinwaldLT,CarterD, normalaging.CerebCortex18:1856-1864. etal.2009.AbsenceofPittsburghCompoundBdetection DaselaarSM,PrinceSE,CabezaR.2004.Whenlessmeans ofcerebralamyloidbinapatientwithclinical,cognitive, more:Deactivationsduringencodingthatpredictsubse- and cerebrospinal fluid markers of Alzheimer disease. quentmemory.Neuroimage23:921-927. ArchNeurol66:1557-1562. DeCarliC,FrisoniGB,ClarkCM,HarveyD,GrundmanM, CardenasVA,ChaoLL,StudholmeC,YaffeK,MillerBL, PetersenRC,ThalLJ,JinS,JackCRJr,ScheltensP.2007. Madison C, Buckley ST, Mungas D, Schuff N, Weiner Qualitativeestimatesofmedialtemporalatrophyasapre- MW.2009.Brainatrophyassociatedwithbaselineand dictorofprogressionfrommildcognitiveimpairmentto longitudinalmeasuresofcognition.NeurobiolAging32: dementia.ArchNeurol64:108-115. 572-580. DeKoskyST,IkonomovicMD,StyrenSD,BeckettL,Wis- Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM. niewskiS,BennettDA,CochranEJ,KordowerJH,Muf- 2008.Correlatingcerebralhypometabolismwithfuture sonEJ.2002.Upregulationofcholineacetyltransferase 16 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease activityinhippocampusandfrontalcortexofelderlysub- EdisonP,ArcherHA,GerhardA,HinzR,PaveseN,Tur- jects with mild cognitive impairment. Ann Neurol 51: kheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, 145-155. et al. 2008. Microglia, amyloid, and cognition in deLeonMJ,ConvitA,WolfOT,TarshishCY,DeSantiS, Alzheimer’s disease: An [11C](R)PK11195-PET and RusinekH,TsuiW,KandilE,SchererAJ,RocheA,etal. [11C]PIB-PETstudy.NeurobiolDis32:412-419. 2001.Predictionofcognitivedeclineinnormalelderly EnglerH,ForsbergA,AlmkvistO,BlomquistG,LarssonE, subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poi- SavitchevaI,WallA,RingheimA,LangstromB,Nord- tron-emissiontomography(FDG/PET).ProcNatlAcad bergA.2006.Two-yearfollow-upofamyloiddeposition Sci98:10966-10971. in patients with Alzheimer’s disease. Brain 129: DeSantiS,deLeonMJ,RusinekH,ConvitA,TarshishCY, 2856-2866. RocheA,TsuiWH,KandilE,BoppanaM,DaisleyK,etal. EnglerH,SantilloAF,WangSX,LindauM,SavitchevaI, 2001.Hippocampalformationglucosemetabolismand NordbergA,LannfeltL,LangstromB,KilanderL.2008. volume losses in MCI and AD. Neurobiol Aging 22: In vivo amyloid imaging with PET in frontotemporal 529-539. dementia.EurJNuclMedMolImaging35:100-106. DevanandDP,MikhnoA,PeltonGH,CuasayK,Pradhaban Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, G,KumarJS,UptonN,LaiR,GunnRN,LibriV,etal. Holtzman DM. 2007. Cerebrospinal fluid tau/b- 2010.PittsburghCompoundB(11C-PIB)andFluoro- amyloid 42 ratio as a prediction of cognitive decline in deoxyglucose(18F-FDG)PETinpatientswithAlzheimer nondementedolderadults.ArchNeurol64:343-349. disease,mildcognitiveimpairment,andhealthycontrols. FaganAM,MintunMA,ShahAR,AldeaP,RoeCM,Mach JGeriatrPsychiatryNeurol23:185-198. RH,MarcusD,MorrisJC,HoltzmanDM.2009.Cerebro- DickersonBC,SperlingRA.2008.Functionalabnormalities spinalfluidtauandptau 181 increasewithcorticalamy- ofthemedialtemporallobememorysysteminmildcog- loid deposition in cognitively normal individuals: nitiveimpairmentandAlzheimer’sdisease:Insightsfrom ImplicationsforfutureclinicaltrialsofAlzheimer’sdis- functionalMRIstudies.Neuropsychologia46:1624-1635. ease.EMBOMolMed1:371-380. DickersonBC,GoncharovaI,SullivanMP,ForchettiC,Wil- FilippiniN,MacIntoshBJ,HoughMG,GoodwinGM,Fri- son RS, Bennett DA, Beckett LA, deToledo-Morrell L. soni GB, Smith SM, Matthews PM, Beckmann CF, 2001.MRI-derivedentorhinalandhippocampalatrophy MackayCE.2009.Distinctpatternsofbrainactivityin inincipientandverymildAlzheimer’sdisease.Neurobiol young carriers of the APOE-14 allele. Proc Natl Acad Aging22:747-754. Sci106:7209-7214. DickersonBC,SalatDH,BatesJF,AtiyaM,KillianyRJ,Greve FleisherAS,HoustonWS,EylerLT,FryeS,JenkinsC,Thal DN,DaleAM,SternCE,BlackerD,AlbertMS,etal.2004. LJ,BondiMW.2005.IdentificationofAlzheimerdisease Medialtemporallobefunctionandstructureinmildcog- risk by functional magnetic resonance imaging. Arch nitiveimpairment.AnnNeurol56:27-35. Neurol62:1881-1888. DickersonBC,SalatD,GreveD,ChuaE,Rand-Giovannetti Fleisher AS, Sherzai A, Taylor C, Langbaum JB,Chen K, E,RentzD,BertramL,MullinK,TanziR,BlackerD,etal. BuxtonRB.2009.Resting-stateBOLDnetworksversus 2005.Increasedhippocampalactivationinmildcognitive task-associated functional MRI for distinguishing Alz- impairmentcomparedtonormalagingandAD.Neurol- heimer’sdiseaseriskgroups.Neuroimage47:1678-1690. ogy65:404-411. ForsbergA,EnglerH,AlmkvistO,BlomquistG,HagmanG, DrzezgaA,GrimmerT,HenriksenG,StangierI,Perneczky WallA,RingheimA,LangstromB,NordbergA.2008. R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, PET imaging of amyloid deposition in patients with DekoskyS,etal.2008.Imagingofamyloidplaquesand mild cognitive impairment. Neurobiol Aging 29: cerebralglucosemetabolisminsemanticdementiaand 1456-1465. Alzheimer’sdisease.Neuroimage39:619-633. ForsbergA,AlmkvistO,EnglerH,WallA,LangstromB, DrzezgaA,GrimmerT,HenriksenG,MuhlauM,Perneczky NordbergA.2010.HighPIBretentioninAlzheimer’sdis- R, Miederer I, Praus C, Sorg C, Wohlschlager A, easeisanearlyeventwithcomplexrelationshipwithCSF RiemenschneiderM,etal.2009.EffectofAPOEgenotype biomarkersandfunctionalparameters.CurrAlzheimer on amyloid plaque load and gray matter volume in Res7:56-66. Alzheimerdisease.Neurology72:1487-1494. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, DuaraR,LoewensteinDA,PotterE,AppelJ,GreigMT,Urs Di Chiro G. 1983. Alzheimer’s disease: Focal cortical R,ShenQ,RajA,SmallB,BarkerW,etal.2008.Medial changes shown by positron emission tomography. temporallobeatrophyonMRIscansandthediagnosisof Neurology33:961-965. Alzheimerdisease.Neurology71:1986-1992. FosterNL,HeidebrinkJL,ClarkCM,JagustWJ,ArnoldSE, DuboisB,FeldmanHH,JacovaC,DekoskyST,Barberger- BarbasNR,DeCarliCS,TurnerRS,KoeppeRA,Higdon Gateau P, Cummings J, Delacourte A, Galasko D, R, et al. 2007. FDG-PET improves accuracy in distin- Gauthier S, Jicha G, et al. 2007. Research criteria for guishingfrontotemporaldementiaandAlzheimer’sdis- the diagnosis of Alzheimer’s disease: Revising the ease.Brain130:2616-2635. NINCDS-ADRDAcriteria.LancetNeurol6:734-746. FoxNC,WarringtonEK,RossorMN.1999a.Serialmagnetic EdisonP,ArcherHA,HinzR,HammersA,PaveseN,TaiYF, resonance imaging of cerebral atrophy in preclinical HottonG,CutlerD,FoxN,KennedyA,etal.2007.Amy- Alzheimer’sdisease.Lancet353:2125. loid,hypometabolism,andcognitioninAlzheimerdis- FoxNC,ScahillRI,CrumWR,RossorMN.1999b.Correla- ease:An[11C]PIBand[18F]FDGPETstudy.Neurology tionbetweenratesofbrainatrophyandcognitivedecline 68:501-508. inAD.Neurology52:1687-1689. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 17 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. FoxNC,CousensS,ScahillR,HarveyRJ,RossorMN.2000. encodinginmildcognitiveimpairment.NeurobiolAging Usingserialregisteredbrainmagneticresonanceimaging 28:1889-1903. to measure disease progression in Alzheimer disease: HanSD,HoustonWS,JakAJ,EylerLT,NagelBJ,FleisherAS, Powercalculationsandestimatesofsamplesizetodetect BrownGG,Corey-BloomJ,SalmonDP,ThalLJ,etal. treatmenteffects.ArchNeurol57:339-344. 2007.Verbalpaired-associatelearningbyAPOEgenotype FoxNC,BlackRS,GilmanS,RossorMN,GriffithSG,Jen- innon-dementedolderadults:fMRIevidenceofaright kins L, Koller M. 2005a. Effects of Ab immunization hemispheric compensatory response. Neurobiol Aging (AN1792) on MRI measures of cerebral volume in 28:238-247. Alzheimerdisease.Neurology64:1563-1572. HanssonO,ZetterbergH,BuchhaveP,LondosE,Blennow FoxMD,SnyderAZ,VincentJL,CorbettaM,VanEssenDC, K, Minthon L. 2006. Association between CSF bio- Raichle ME. 2005b. The human brain is intrinsically markers and incipient Alzheimer’s disease in patients organizedintodynamic,anticorrelatedfunctionalnet- with mild cognitive impairment: A follow-up study. works.ProcNatlAcadSci102:9673-9678. LancetNeurol5:228-234. FrisoniGB,FoxNC,JackCRJr,ScheltensP,ThompsonPM. HeddenT,VanDijkKR,BeckerJA,MehtaA,SperlingRA, 2010. The clinical use of structural MRIin Alzheimer JohnsonKA,BucknerRL.2009.Disruptionoffunctional disease.NatRevNeurol6:67-77. connectivityinclinicallynormalolderadultsharboring FurstAJ,RabinoviciGD,RostomianAH,SteedT,AlkalayA, amyloidburden.JNeurosci29:12686-12694. Racine C, Miller BL, Jagust WJ. 2010. Cognition, HeunR,FreymannK,ErbM,LeubeDT,JessenF,KircherTT, glucosemetabolismandamyloidburdeninAlzheimer’s GroddW.2007.Mildcognitiveimpairment(MCI)and disease. Neurobiol Aging (in press). doi: 10.1016/ actualretrievalperformanceaffectcerebralactivationin j.neurobiolaging.2010.03.011. theelderly.NeurobiolAging28:404-413. GanguliM,DodgeHH,ShenC,DeKoskyST.2004.Mild Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, cognitiveimpairment,amnestictype:anepidemiologic HuletteC,EarlN,ColemanRE.2000.FDGPETimaging study.Neurology63:115-121. inpatientswithpathologicallyverifieddementia.JNucl GoekoopR,RomboutsSA,JonkerC,HibbelA,KnolDL, Med41:1920-1928. TruyenL,BarkhofF,ScheltensP.2004.Challengingthe HuaX,LeowAD,ParikshakN,LeeS,ChiangMC,TogaAW, cholinergicsysteminmildcognitiveimpairment:Aphar- JackCRJr,WeinerMW,ThompsonPM.2008.Tensor- macologicalfMRIstudy.Neuroimage23:1450-1459. based morphometry as a neuroimaging biomarker for GolbyA,SilverbergG,RaceE,GabrieliS,O’SheaJ,Knierim Alzheimer’s disease: An MRI study of 676 AD, MCI, K,StebbinsG,GabrieliJ.2005.MemoryencodinginAlz- andnormalsubjects.Neuroimage43:458-469. heimer’sdisease:AnfMRIstudyofexplicitandimplicit IbanezV,PietriniP,AlexanderGE,FureyML,TeichbergD, memory.Brain128:773-787. Rajapakse JC, Rapoport SI, Schapiro MB, Horwitz B. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, 1998.Regionalglucosemetabolicabnormalitiesarenot SnowdonDA.2002.Hippocampalvolumeasanindex theresultofatrophy inAlzheimer’s disease.Neurology of Alzheimer neuropathology: Findings from the Nun 50:1585-1593. Study.Neurology58:1476-1482. IkonomovicMD,KlunkWE,AbrahamsonEE,MathisCA, GradyCL,McIntoshAR,BeigS,KeightleyML,BurianH, PriceJC,TsopelasND,LoprestiBJ,ZiolkoS,BiW,Paljug BlackSE.2003.Evidencefromfunctionalneuroimaging WR,etal.2008.Post-mortemcorrelatesofinvivoPiB- ofacompensatoryprefrontalnetworkinAlzheimer’sdis- PETamyloidimaginginatypicalcaseofAlzheimer’sdis- ease.JNeurosci23:986-993. ease.Brain131:1630-1645. Greicius MD, Srivastava G, Reiss AL, Menon V. 2004. JackCRJr,DicksonDW,ParisiJE,XuYC,ChaRH,O’Brien Default-modenetworkactivitydistinguishesAlzheimer’s PC,EdlandSD,SmithGE,BoeveBF,TangalosEG,etal. disease from healthy aging: Evidence from functional 2002.AntemortemMRIfindingscorrelatewithhippo- MRI.ProcNatlAcadSci101:4637-4642. campalneuropathologyintypicalaginganddementia. GrimmerT, Riemenschneider M, Forstl H, Henriksen G, Neurology58:750-757. Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, JackCRJr,ShiungMM,GunterJL,O’BrienPC,Weigand DrzezgaA.2009.BetaamyloidinAlzheimer’sDisease: SD,KnopmanDS,BoeveBF,IvnikRJ,SmithGE,Cha Increaseddepositioninbrainisreflectedinreducedcon- RH,etal.2004.ComparisonofdifferentMRIbrainatro- centration in cerebrospinal fluid. Biol Psychiatry 65: phyratemeasureswithclinicaldiseaseprogressioninAD. 927-934. Neurology62:591-600. GronG,BittnerD,SchmitzB,WunderlichAP,RiepeMW. JackCRJr,PetersenRC,GrundmanM,JinS,GamstA,Ward 2002.Subjectivememorycomplaints:Objectiveneural CP,SencakovaD,DoodyRS,ThalLJ.2008a.Longitudinal markersinpatientswithAlzheimer’sdiseaseandmajor MRIfindingsfromthevitaminEanddonepeziltreat- depressivedisorder.AnnNeurol51:491-498. mentstudyforMCI.NeurobiolAging29:1285-1295. Hamalainen A, Pihlajamaki M, Tanila H, Hanninen T, Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, Niskanen E, Tervo S, Karjalainen PA, Vanninen RL, O’BrienPC,GunterJL,KnopmanDS,BoeveBF,Smith Soininen H. 2006. Increased fMRI responses during GE, Petersen RC. 2008b. Atrophy rates accelerate in encodinginmildcognitiveimpairment.NeurobiolAging amnestic mild cognitive impairment. Neurology 70: 28:1889-1903. 1740-1752. Hamalainen A, Pihlajamaki M, Tanila H, Hanninen T, JackCRJr,LoweVJ,WeigandSD,WisteHJ,SenjemML, NiskanenE,TervoS,KarjalainenPA,VanninenRL,Soi- KnopmanDS,ShiungMM,GunterJL,BoeveBF,Kemp ninen H. 2007. Increased fMRI responses during BJ, et al. 2009. Serial PIB and MRI in normal, mild 18 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease cognitiveimpairmentandAlzheimer’sdisease:Implica- relationtoeducationinmildAlzheimer’sdisease.Ann tionsforsequenceofpathologicaleventsinAlzheimer’s Neurol63:112-118. disease.Brain132:1355-1365. KillianyRJ,HymanBT,Gomez-IslaT,MossMB,KikinisR, JackCRJr,KnopmanDS,JagustWJ,ShawLM,AisenPS, JoleszF,TanziR,JonesK,AlbertMS.2002.MRImeasures WeinerMW,PetersenRC,TrojanowskiJQ.2010.Hypo- ofentorhinalcortexvshippocampusinpreclinicalAD. theticalmodelofdynamicbiomarkersoftheAlzheimer’s Neurology58:1188-1196. pathologicalcascade.LancetNeurol9:119-128. KircherTT,WeisS,FreymannK,ErbM,JessenF,GroddW, JagustWJ,EberlingJL,WuCC,FinkbeinerA,MungasD, Heun R, Leube DT. 2007. Hippocampal activation in ValkPE,HaanMN.2002.Brainfunctionandcognition patients with mild cognitive impairment is necessary in a community sample of elderly Latinos. Neurology for successful memory encoding. J Neurol Neurosurg 59:378-383. Psychiatry78:812-818. JagustW,GitchoA,SunF,KuczynskiB,MungasD,HaanM. KloppelS,StonningtonCM,ChuC,DraganskiB,ScahillRI, 2006.BrainimagingevidenceofpreclinicalAlzheimer’s RohrerJD,FoxNC,JackCRJr,AshburnerJ,Frackowiak diseaseinnormalaging.AnnNeurol59:673-681. RS. 2008. Automatic classification of MR scans in JagustW,ReedB,MungasD,EllisW,DecarliC.2007.What Alzheimer’sdisease.Brain131:681-689. doesfluorodeoxyglucosePETimagingaddtoaclinical KlunkWE,WangY,HuangGF,DebnathML,HoltDP,Shao diagnosisofdementia?Neurology69:871-877. L,HamiltonRL,IkonomovicMD,DeKoskyST,Mathis JagustWJ,LandauSM,ShawLM,TrojanowskiJQ,Koeppe CA. 2003. The binding of 2-(40-methylaminophenyl)- RA,ReimanEM,FosterNL,PetersenRC,WeinerMW, benzothiazole to postmortem brain homogenates is PriceJC,etal.2009.Relationshipsbetweenbiomarkers dominated by the amyloid component. J Neurosci 23: inaginganddementia.Neurology73:1193-1199. 2086-2092. JagustWJ,BandyD,ChenK,FosterNL,LandauSM,Mathis KlunkWE,EnglerH,NordbergA,WangY,BlomqvistG, CA,PriceJC,ReimanEM,SkovronskyD,KoeppeRA. HoltDP,Bergstro¨mM,SavitchevaI,HuangGF,Estrada 2010. The Alzheimer’s Disease neuroimaging initiative S,etal.2004.ImagingbrainamyloidinAlzheimer’sdis- positronemissiontomographycore.AlzheimersDement ease with Pittsburgh Compound-B. Ann Neurol 55: 6:221-229. 306-319. JohnsonSC,SchmitzTW,MoritzCH,MeyerandME,Row- KnopmanDS,DeKoskyST,CummingsJL,ChuiH,Corey- leyHA,AlexanderAL,HansenKW,GleasonCE,Carlsson BloomJ,RelkinN,SmallGW,MillerB,StevensJC.2001. CM,RiesML,etal.2006.Activationofbrainregionsvul- Practiceparameter:Diagnosisofdementia(anevidence- nerabletoAlzheimer’sdisease:Theeffectofmildcogni- based review). Report of the quality standards tiveimpairment.NeurobiolAging27:1604-1612. subcommitteeoftheAmericanAcademyofNeurology. JohnsonKA,GregasM,BeckerJA,KinnecomC,SalatDH, Neurology56:1143-1153. MoranEK,SmithEE,RosandJ,RentzDM,KlunkWE, Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, etal.2007.Imagingofamyloidburdenanddistribution Bokde AL, Hampel H, Coates U, Reiser M, Meindl T. incerebralamyloidangiopathy.AnnNeurol62:229-234. 2010. Diagnostic power of default mode network KadirA,AndreasenN,AlmkvistO,WallA,ForsbergA,Eng- restingstatefMRIinthedetectionofAlzheimer’sdisease. lerH,HagmanG,LarksaterM,WinbladB,ZetterbergH, Neurobiol Aging (in press). doi: 10.1016/j.neuro- etal.2008.Effectofphenserinetreatmentonbrainfunc- biolaging2010.04.013. tionalactivityandamyloidinAlzheimer’sdisease.Ann KoivunenJ,PirttilaT,KemppainenN,AaltoS,HerukkaSK, Neurol63:621-631. JauhianenAM,HanninenT,HallikainenM,NagrenK, KadirA,AlmkvistO,ForsbergA,WallA,EnglerH,Lang- Rinne JO, et al. 2008. PETamyloid ligand [11C]PIB strom B,Nordberg A. 2010.Dynamicchangesin PET uptakeandcerebrospinalfluidb-amyloidinmildcogni- amyloid and FDG imaging at different stages of tiveimpairment.DementGeriatrCognDisord26:378- Alzheimer’s disease. Neurobiol Aging (in press). doi: 383. 10.1016/j.neurobiolaging.2010.06.015. KorfES,WahlundLO,VisserPJ,ScheltensP.2004.Medial KarowDS,McEvoyLK,Fennema-NotestineC,HaglerDJJr, temporal lobe atrophy on MRI predicts dementia in JenningsRG,BrewerJB,HohCK,DaleAM.2010.Rela- patientswithmildcognitiveimpairment.Neurology63: tivecapabilityofMRimagingandFDGPETtodepict 94-100. changesassociatedwithprodromalandearlyAlzheimer KukoljaJ,ThielCM,FinkGR.2009.Cholinergicstimula- disease.Radiology256:932-942. tionenhancesneuralactivityassociatedwithencoding KatoT,KnopmanD,LiuH.2001.Dissociationofregional but reduces neural activityassociated with retrieval in activationinmildADduringvisualencoding:Afunc- humans.JNeurosci29:8119-8128. tionalMRIstudy.Neurology57:812-816. KwongKK,BelliveauJW,CheslerDA,GoldbergIE,Weissk- KemppainenNM,AaltoS,WilsonIA,NagrenK,HelinS, offRM,PonceletBP,KennedyDN,HoppelBE,Cohen BruckA,OikonenV,KailajarviM,ScheininM,Viitanen MS,TurnerR,etal.1992.Dynamicmagneticresonance M,etal.2006.Voxel-basedanalysisofPETamyloidligand imagingofhumanbrainactivityduringprimarysensory [11C]PIB uptake in Alzheimer disease. Neurology 67: stimulation.ProcNatlAcadSci89:5675-5679. 1575-1580. LandauSM,HarveyD,MadisonCM,ReimanEM,Foster KemppainenNM,AaltoS,KarraschM,NagrenK,SavistoN, NL,AisenPS,PetersenRC,ShawLM,TrojanowskiJQ, OikonenV,ViitanenM,ParkkolaR,RinneJO.2008.Cog- JackCRJr,etal.2010.Comparingpredictorsofconver- nitivereservehypothesis:PittsburghCompoundBand sionanddeclineinmildcognitiveimpairment.Neurol- fluorodeoxyglucose positron emission tomography in ogy75:230-238. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 19 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. LangbaumJB,ChenK,LeeW,ReschkeC,BandyD,Fleisher MagistrettiPJ.2006.Neuron-gliametaboliccouplingand AS,AlexanderGE,FosterNL,WeinerMW,KoeppeRA, plasticity.JExpBiol209:2304-2311. etal.2009.Categoricalandcorrelationalanalysesofbase- MasliahE,AlfordM,AdameA,RockensteinE,GalaskoD, linefluorodeoxyglucosepositronemissiontomography SalmonD,HansenLA,ThalLJ.2003.Ab1-42promotes imagesfromtheAlzheimer’sDiseaseNeuroimagingIni- cholinergicsproutinginpatientswithADandLewybody tiative(ADNI).Neuroimage45:1107-1116. variantofAD.Neurology61:206-211. LarrieuS,LetenneurL,OrgogozoJM,FabrigouleC,Amieva McKeithIG,DicksonDW,LoweJ,EmreM,O’BrienJT,Feld- H,LeCarretN,Barberger-GateauP,DartiguesJF.2002. manH,CummingsJ,DudaJE,LippaC,PerryEK,etal. Incidence and outcome of mild cognitive impairment 2005.DiagnosisandmanagementofdementiawithLewy in a population-based prospective cohort. Neurology bodies:ThirdreportoftheDLBConsortium.Neurology 59:1594-1599. 65:1863-1872. LehericyS,BaulacM,ChirasJ,PierotL,MartinN,PillonB, MeltzerCC,ZubietaJK,BrandtJ,TuneLE,MaybergHS, DeweerB,DuboisB,MarsaultC.1994.Amygdalohippo- FrostJJ.1996.RegionalhypometabolisminAlzheimer’s campalMRvolumemeasurementsintheearlystagesof diseaseasmeasuredby positronemissiontomography Alzheimerdisease.AmJNeuroradiol15:929-937. aftercorrectionforeffectsofpartialvolumeaveraging. LenziD,SerraL,PerriR,PantanoP,LenziGL,PaulesuE, Neurology47:454-461. Caltagirone C, Bozzali M, Macaluso E. 2009. Single MillerSL,FenstermacherE,BatesJ,BlackerD,SperlingRA, domain amnestic MCI: A multiple cognitive domains DickersonBC.2008a.Hippocampalactivationinadults fMRIinvestigation.NeurobiolAging32:1542-1557. with mild cognitive impairment predicts subsequent LerchJP,PruessnerJC,ZijdenbosA,HampelH,TeipelSJ, cognitive decline. J Neurol Neurosurg Psychiatry 79: EvansAC.2005.FocaldeclineofcorticalthicknessinAlz- 630-635. heimer’sdiseaseidentifiedbycomputationalneuroanat- MillerSL,CeloneK,DePeauK,DiamondE,DickersonBC, omy.CerebCortex15:995-1001. RentzD,PihlajamakiM,SperlingRA.2008b.Age-related LikemanM,AndersonVM,StevensJM,WaldmanAD,God- memory impairment associated with loss of parietal bolt AK, Frost C, Rossor MN, Fox NC. 2005. Visual deactivation but preserved hippocampal activation. assessment ofatrophyonmagneticresonanceimaging ProcNatlAcadSci105:2181-2186. inthediagnosisofpathologicallyconfirmedyoung-onset MinoshimaS,GiordaniB,BerentS,FreyKA,FosterNL, dementias.ArchNeurol62:1410-1415. Kuhl DE. 1997. Metabolic reduction in the posterior LindJ,IngvarM,PerssonJ,SleegersK,VanBroeckhovenC, cingulatecortex inveryearlyAlzheimer’s disease.Ann AdolfssonR,NilssonLG,NybergL.2006a.Parietalcortex Neurol42:85-94. activationpredictsmemorydeclineinapolipoproteinE- Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, 14carriers.Neuroreport17:1683-1686. MachRH,KlunkWE,MathisCA,DeKoskyST,Morris LindJ,LarssonA,PerssonJ,IngvarM,NilssonLG,Backman JC,etal.2006.[11C]PIBinanondementedpopulation: L,AdolfssonR,CrutsM,SleegersK,VanBroeckhovenC, Potential antecedent marker of Alzheimer disease. et al. 2006b. Reduced hippocampal volume in non- Neurology67:446-52. dementedcarriersoftheapolipoproteinE14:Relation MisraC,FanY,DavatzikosC.2009.Baselineandlongitudi- tochronologicalageandrecognitionmemory.Neurosci nalpatternsofbrainatrophyinMCIpatients,andtheir Lett396:23-27. useinpredictionofshort-termconversiontoAD:Results LockhartA,LambJR,OsredkarT,SueLI,JoyceJN,YeL, fromADNI.Neuroimage44:1415-1422. LibriV,LeppertD,BeachTG.2007.PIBisanon-specific MitchellAJ,Shiri-FeshkiM.2009.Rateofprogressionof imagingmarkerofamyloid-b(Ab)peptide-relatedcere- mildcognitiveimpairmenttodementia-Meta-analysis bralamyloidosis.Brain130:2607-2615. of 41 robust inception cohort studies. Acta Psychiatr LogothetisNK,PaulsJ,AugathM,TrinathT,OeltermannA. Scand119:252-265. 2001.Neurophysiologicalinvestigationofthebasisofthe MondadoriCR,deQuervainDJ,BuchmannA,MustovicH, fMRIsignal.Nature412:150-157. WollmerMA,SchmidtCF,BoesigerP,HockC,Nitsch LoweVJ,KempBJ,JackCRJr,SenjemM,WeigandS,Shiung RM, Papassotiropoulos A, et al. 2007. Better memory M,SmithG,KnopmanD,BoeveB,MullanB,etal.2009. andneuralefficiencyinyoungapolipoproteinE14car- Comparison of 18F-FDG and PiB PET in cognitive riers.CerebCortex17:1934-1947. impairment.JNuclMed50:878-886. MorrisJC,RoeCM,XiongC,FaganAM,GoateAM,Holtz- Lustig C, Buckner RL. 2004. Preserved neural correlates manDM,MintunMA.2010.APOEpredictsamyloid-b ofpriminginoldageanddementia.Neuron42:865- butnottauAlzheimerpathologyincognitivelynormal 875. aging.AnnNeurol67:122-131. MachuldaMM,WardHA,BorowskiB,GunterJL,ChaRH, Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, O’BrienPC,PetersenRC,BoeveBF,KnopmanD,Tang- LucignaniG,ReimanEM,HolthoffV,KalbeE,SorbiS, Wai DF, et al. 2003. Comparison of memory fMRI etal.2008.Multicenterstandardized18F-FDGPETdiag- responseamongnormal,MCI,andAlzheimer’spatients. nosisofmildcognitiveimpairment,Alzheimer’sdisease, Neurology61:500-506. andotherdementias.JNuclMed49:390-398. Maetzler W, Liepelt I, ReimoldM, ReischlG, Solbach C, MosconiL,MisturR,SwitalskiR,BrysM,GlodzikL,RichK, BeckerC,SchulteC,LeyheT,KellerS,MelmsA,etal. PirragliaE,TsuiW,DeSantiS,deLeonMJ.2009.Declin- 2009.CorticalPIBbindinginLewybodydiseaseisasso- ingbrainglucosemetabolisminnormalindividualswith ciatedwithAlzheimer-likecharacteristics.NeurobiolDis amaternalhistoryofAlzheimerdisease.Neurology72: 34:107-112. 513-520. 20 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease MosconiL,RinneJO,TsuiWH,BertiV,LiY,WangH,Mur- PutchaD,O’KeefeK,LaVioletteP,O’BrienJ,GreveD,Rentz ray J, Scheinin N, Nagren K, Williams S, et al. 2010. D, Locascio JJ, Atri A, Sperling R. 2010. Reliabilityof Increasedfibrillaramyloid-bburdeninnormalindivid- fMRI associative encoding memory paradigm in non- ualswithafamilyhistoryoflate-onsetAlzheimer’s.Proc demented elderly adults. Human Brain Mapping (in NatlAcadSci107:5949-5954. press).doi:10.1002/hbm.21166. (cid:2) MuckeL,SelkoeDJ.2011.Neurotoxicityofamyloidb-pro- RabinoviciGD,FurstAJ,O’NeilJP,RacineCA,Mormino tein: Synaptic and network dysfunction. Cold Spring EC,BakerSL,ChettyS,PatelP,PagliaroTA,KlunkWE, HarbPerspectMeddoi:10.1101/cshperspect.a006338. etal.2007.11C-PIBPETimaginginAlzheimerdisease NelissenN,VanLaereK,ThurfjellL,OweniusR,Vanden- and frontotemporal lobar degeneration. Neurology 68: bulcke M, Koole M, Bormans G, Brooks DJ, Vanden- 1205-1212. berghe R. 2009. Phase 1 study of the Pittsburgh RabinoviciGD,JagustWJ,FurstAJ,OgarJM,RacineCA, Compound B derivative 18F-Flutemetamol in healthy Mormino EC, O’Neil JP, Lal RA, Dronkers NF, Miller volunteersandpatientswithprobableAlzheimerdisease. BL,etal.2008.Abamyloidandglucosemetabolismin JNuclMed50:1251-1259. threevariantsofprimaryprogressiveaphasia.AnnNeurol O’BrienJL,O’KeefeKM,LaViolettePS,DeLucaAN,Blacker 64:388-401. D,DickersonBC,SperlingRA.2010.LongitudinalfMRI RabinoviciGD,FurstAJ,AlkalayA,RacineCA,O’NeilJP, in elderly reveals loss of hippocampal activation with JanabiM,BakerSL,AgarwalN,BonaseraSJ,Mormino clinicaldecline.Neurology74:1969-1976. EC, et al. 2010. Increased metabolic vulnerability in OgawaS,LeeTM,NayakAS,GlynnP.1990.Oxygenation- early-onsetAlzheimer’sdiseaseisnotrelatedtoamyloid sensitivecontrastinmagneticresonanceimageofrodent burden.Brain133:512-528. brain at high magnetic fields. Magn Reson Med 14: RaichleME,MacLeodAM,SnyderAZ,PowersWJ,Gusnard 68-78. DA,ShulmanGL.2001.Adefaultmodeofbrainfunc- OkelloA,KoivunenJ,EdisonP,ArcherHA,TurkheimerFE, tion.ProcNatlAcadSci98:676-682. NagrenK,BullockR,WalkerZ,KennedyA,FoxNC,etal. ReimanEM,CaselliRJ,YunLS,ChenK,BandyD,Minosh- 2009.ConversionofamyloidpositiveandnegativeMCI imaS,ThibodeauSN,OsborneD.1996.Preclinicalevi- toADover3years:An11C-PIBPETstudy.Neurology dence of Alzheimer’s disease in persons homozygous 73:754-760. forthe14alleleforapolipoproteinE.NewEnglJMed PalopJJ,ChinJ,RobersonED,WangJ,ThwinMT,Bien-Ly 334:752-758. N,YooJ,HoKO,YuGQ,KreitzerA,etal.2007.Aberrant excitatoryneuronalactivityandcompensatoryremodel- Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy ingofinhibitoryhippocampalcircuitsinmousemodels D, Osborne D, Saunders AM, Hardy J. 2005. Correla- ofAlzheimer’sdisease.Neuron55:697-711. tions between apolipoprotein E 14 gene dose and brain-imagingmeasurementsofregionalhypometabo- PetersenRC.2004.Mildcognitiveimpairmentasadiagnos- lism.ProcNatlAcadSci102:8299-8302. ticentity.JInternMed256:183-194. ReimanEM,ChenK,CaselliRJ,AlexanderGE,BandyD, PetersenRC,SmithGE,WaringSC,IvnikRJ,TangalosE, AdamsonJL, LeeW, CannonA, StephanEA,Stephan Kokmen E. 1999. Mild cognitive impairment. Clinical DA, et al. 2008. Cholesterol-related genetic risk scores characterizationandoutcome.ArchNeurol56:303-308. are associated with hypometabolism in Alzheimer’s- PetrellaJ,KrishnanS,SlavinM,TranT-T,MurtyL,Doraisw- affectedbrainregions.Neuroimage40:1214-1221. amyP.2006.Mildcognitiveimpairment:Evaluationwith 4-TfunctionalMRimaging.Radiology240:177-186. Reiman EM, Chen K, Langbaum JB, Lee W, Reschke C, BandyD,AlexanderGE,CaselliRJ.2010.Higherserum PetrellaJR, PrinceSE,WangL,HellegersC,Doraiswamy totalcholesterollevelsinlatemiddleageareassociated PM. 2007a. Prognostic value of posteromedial cortex withglucosehypometabolisminbrainregionsaffected deactivationinmildcognitiveimpairment.PLoSOne2: by Alzheimer’s disease and normal aging. Neuroimage e1104. 49:169-176. PetrellaJR,WangL,KrishnanS,SlavinMJ,PrinceSE,Tran RemyF,MirrashedF,CampbellB,RichterW.2004.Mental TT, Doraiswamy PM. 2007b. Cortical deactivation in calculationimpairmentinAlzheimer’sdisease:Afunc- mild cognitive impairment: High-field-strength func- tionalmagneticresonanceimagingstudy.NeurosciLett tionalMRimaging.Radiology245:224-235. 358:25-28. PetrieEC,CrossDJ,GalaskoD,SchellenbergGD,Raskind MA, Peskind ER, Minoshima S. 2009. Preclinical evi- RentzDM,LocascioJJ,BeckerJA,MoranEK,EngE,Buck- dence of Alzheimerchanges:Convergentcerebrospinal ner RL, Sperling RA, Johnson KA. 2010. Cognition, fluidbiomarkerandfluorodeoxyglucosepositronemis- reserve,andamyloiddepositioninnormalaging.Ann siontomographyfindings.ArchNeurol66:632-637. Neurol67:353-364. PihlajamakiM,DepeauKM,BlackerD,SperlingRA.2008. RidhaBH,BarnesJ,BartlettJW,GodboltA,PeppleT,Rossor Impaired medial temporal repetition suppression is MN,FoxNC.2006.Trackingatrophyprogressioninfam- related to failure of parietal deactivation in Alzheimer ilialAlzheimer’sdisease:AserialMRIstudy.LancetNeu- disease.AmJGeriatrPsychiatry16:283-292. rol5:828-834. PihlajamakiM,O’KeefeK,BertramL,TanziR,DickersonB, RidhaBH,AndersonVM,BarnesJ,BoyesRG,PriceSL,Ros- BlackerD,AlbertM,SperlingR.2009.Evidenceofaltered sorMN,WhitwellJL,JenkinsL,BlackRS,GrundmanM, posteromedialcorticalfMRIactivityinsubjectsatrisk etal.2008.VolumetricMRIandcognitivemeasuresin for Alzheimer disease. Alzheimer Dis Assoc Disord 24: Alzheimerdisease:Comparisonofmarkersofprogres- 28-36. sion.JNeurol255:567-574. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 21 gro.enicidemnisevitcepsrep.www K.A.Johnsonetal. RingmanJM,MedinaLD,BraskieM,Rodriguez-AgudeloY, SavvaGM,WhartonSB,IncePG,ForsterG,MatthewsFE, GeschwindDH,Macias-IslasMA,CummingsJL,Book- Brayne C. 2009. Age, neuropathology, and dementia. heimerS.2010.EffectsofriskgenesonBOLDactivation NewEnglJMed360:2302-2309. inpresymptomaticcarriersoffamilialAlzheimer’sdis- SaykinAJ,WishartHA,RabinLA,FlashmanLA,McHugh ease mutations during a novelty encoding task. Cereb TL, Mamourian AC, Santulli RB. 2004. Cholinergic Cortex21:877-883. enhancementoffrontallobeactivity inmildcognitive RinneJO,BrooksDJ,RossorMN,FoxNC,BullockR,Klunk impairment.Brain127:1574-1583. WE,MathisCA,BlennowK,BarakosJ,OkelloAA,etal. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. 2010. (11)C-PiB PETassessment of change in fibrillar 2002.MappingtheevolutionofregionalatrophyinAlz- amyloid-b load in patients with Alzheimer’s disease heimer’s disease: Unbiased analysis of fluid-registered treated with bapineuzumab: A phase 2, double-blind, serialMRI.ProcNatlAcadSci99:4703-4707. placebo-controlled,ascending-dosestudy.LancetNeurol ScheltensP,LeysD,BarkhofF,HugloD,WeinsteinHC,Ver- 9:363-372. mersch P, Kuiper M, Steinling M, Wolters EC, Valk J. RitchieK,ArteroS,TouchonJ.2001.Classificationcriteria 1992. Atrophy of medial temporal lobes on MRI in formildcognitiveimpairment:Apopulation-basedval- “probable”Alzheimer’sdiseaseandnormalageing:Diag- idationstudy.Neurology56:37-42. nosticvalueandneuropsychologicalcorrelates.JNeurol NeurosurgPsychiatry55:967-972. RocherAB,ChaponF,BlaizotX,BaronJC,ChavoixC.2003. Resting-state brain glucose utilization as measured by ScheltensP,FoxN,BarkhofF,DeCarliC.2002.Structural PETisdirectlyrelatedtoregionalsynaptophysinlevels: magneticresonanceimaginginthepracticalassessment Astudyinbaboons.Neuroimage20:1894-1898. of dementia: Beyond exclusion. Lancet Neurol 1: 13-21. Roe CM, Mintun MA, D’Angelo G, Xiong C, Grant EA, MorrisJC.2008.Alzheimerdiseaseandcognitivereserve: SchuffN,WoernerN,BoretaL,KornfieldT,ShawLM,Tro- Variation of education effect with carbon 11-labeled janowskiJQ,ThompsonPM,JackCRJr,WeinerMW. Pittsburgh Compound B uptake. Arch Neurol 65: 2009. MRI of hippocampal volume loss in early Alz- heimer’sdiseaseinrelationtoApoEgenotypeandbio- 1467-1471. markers.Brain132:1067-1077. RoeCM,MintunMA,GhoshalN,WilliamsMM,GrantEA, SchwartzWJ,SmithCB,DavidsenL,SavakiH,SokoloffL, MarcusDS,MorrisJC.2010.Alzheimerdiseaseidentifi- MataM,FinkDJ,GainerH.1979.Metabolicmapping cation using amyloid imaging and reserve variables: of functional activity in the hypothalamo-neurohypo- Proofofconcept.Neurology75:42-48. physialsystemoftherat.Science205:723-725. Rombouts SA, Barkhof F, Veltman DJ, Machielsen WC, (cid:2) SelkoeD,MandelkowE,HoltzmanD.2011.Deciphering WitterMP,BierlaaghMA,LazeronRH,ValkJ,Scheltens Alzheimerdisease.ColdSpringHarbPerspectMeddoi: P.2000.FunctionalMRimaginginAlzheimer’sdisease 10.1101/cshperspect.a011460. duringmemoryencoding.AmJNeuroradiol21:1869- ShanksMF,McGeownWJ,Forbes-McKayKE,WaiterGD, 1875. RiesM,VenneriA.2007.Regionalbrainactivityafterpro- RomboutsSA,BarkhofF,VanMeelCS,ScheltensP.2002. longedcholinergicenhancementinearlyAlzheimer’sdis- Alterations in brain activation during cholinergic ease.MagnResonImaging25:848-859. enhancementwithrivastigmineinAlzheimer’sdisease. Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, JNeurolNeurosurgPsychiatry73:665-671. Wang S, Mintun MA. 2009. Amyloid plaques disrupt RomboutsSA,BarkhofF,GoekoopR,StamCJ,ScheltensP. restingstatedefaultmodenetworkconnectivityincogni- 2005. Altered resting state networks in mild cognitive tivelynormalelderly.BiolPsychiatry67:587-587. impairment and mild Alzheimer’s disease: An fMRI ShinJ,LeeSY,KimSH,KimYB,ChoSJ.2008.Multitracer study.HumBrainMapp26:231-239. PET imaging of amyloid plaques and neurofibrillary Rombouts SA, Damoiseaux JS, Goekoop R, Barkhof F, tanglesinAlzheimer’sdisease.Neuroimage43:236-244. ScheltensP,SmithSM,BeckmannCF.2009.Model-free SibsonNR,DhankharA,MasonGF,BeharKL,Rothman groupanalysisshowsalteredBOLDFMRInetworksin DL,ShulmanRG.1997.Invivo13CNMRmeasurements dementia.HumBrainMapp30:256-266. of cerebral glutamine synthesis as evidence for gluta- RoweCC,AckermanU,BrowneW,MulliganR,PikeKL, mate-glutaminecycling. Proc Natl AcadSci 94:2699- O’KeefeG,Tochon-DanguyH,ChanG,BerlangieriSU, 2704. JonesG,etal.2008.Imagingofamyloid-binAlzheimer’s SmallSA,PereraGM,DeLaPazR,MayeuxR,SternY.1999. disease with (18)F-BAY94-9172, a novel PET tracer: Differential regional dysfunction of the hippocampal Proofofmechanism.LancetNeurol7:129-135. formation among elderly with memory decline and RoweCC,EllisKA,RimajovaM,BourgeatP,PikeKE,Jones Alzheimer’sdisease.AnnNeurol45:466-472. G,FrippJ,Tochon-DanguyH,MorandeauL,O’KeefeG, SmallGW,ErcoliLM,SilvermanDH,HuangSC,KomoS, etal.2010.AmyloidimagingresultsfromtheAustralian BookheimerSY,LavretskyH,MillerK,SiddarthP,Ras- imaging,biomarkersandlifestyle(AIBL)studyofaging. gon NL, et al. 2000. Cerebral metabolic and cognitive NeurobiolAging31:1275-1283. declineinpersonsatgeneticriskforAlzheimer’sdisease. SallowayS,SperlingR,GilmanS,FoxNC,BlennowK,Ras- ProcNatlAcadSci97:6037-6042. kindM,SabbaghM,HonigLS,DoodyR,vanDyckCH, SmithCD, AndersenAH,KryscioRJ,SchmittFA, Kindy etal.2009.Aphase2multipleascendingdosetrialof MS,BlonderLX,AvisonMJ.1999.Alteredbrainactiva- bapineuzumabinmildtomoderateAlzheimerdisease. tionincognitivelyintactindividualsathighriskforAlz- Neurology73:2061-2070. heimer’sdisease.Neurology53:1391-1396. 22 CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 gro.enicidemnisevitcepsrep.www BrainImaginginAlzheimerDisease SmithCD,AndersenAH,KryscioRJ,SchmittFA,Kindy TrivediMA,SchmitzTW,RiesML,TorgersonBM,Sager MS,BlonderLX, Avison MJ. 2002.Womenat risk for MA,HermannBP,AsthanaS,JohnsonSC.2006.Reduced ADshowincreasedparietalactivationduringafluency hippocampal activation during episodic encoding in task.Neurology58:1197-1202. middle-aged individuals at genetic riskof Alzheimer’s Sole-PadullesC,Bartres-FazD,JunqueC,VendrellP,Rami disease:Across-sectionalstudy.BMCMed4:1. L,ClementeIC,BoschB,VillarA,BargalloN,Jurado VandenbergheR,VanLaereK,IvanoiuA,SalmonE,Bastin MA,etal.2009.Brainstructureandfunctionrelatedto C,TriauE,HasselbalchS,LawI,AndersenA,KornerA, cognitivereservevariablesinnormalaging,mildcogni- etal.2010.(18)F-flutemetamolamyloidimaginginAlz- tive impairment and Alzheimer’s disease. Neurobiol heimerdiseaseandmildcognitiveimpairment:Aphase2 Aging30:1114-1124. trial.AnnNeurol68:319-329. SorgC,RiedlV,MuhlauM,CalhounVD,EicheleT,LaerL, VemuriP,WisteHJ,WeigandSD,ShawLM,TrojanowskiJQ, DrzezgaA,ForstlH,KurzA,ZimmerC,etal.2007.Selec- Weiner MW, Knopman DS, Petersen RC, Jack CR Jr. tivechangesofresting-statenetworksinindividualsat 2009. MRIand CSF biomarkers in normal, MCI, and risk for Alzheimer’s disease. Proc Natl Acad Sci 104: ADsubjects:Predictingfutureclinicalchange.Neurology 18760-18765. 73:294-301. SperlingRA,GreveD,DaleA,KillianyR,RosenB,HolmesJ, VenneriA,McGeownWJ,ShanksMF.2009.Respondersto RosasHD,CocchiarellaA,FirthP,LakeS,etal.2002. ChEItreatmentofAlzheimer’sdiseaseshowrestitutionof fMRIdetectionofpharmacologicallyinducedmemory normalregionalcorticalactivation.CurrAlzheimerRes6: impairment.ProcNatlAcadSci99:455-460. 97-111. SperlingR,BatesJ,ChuaE,CocchiarellaA,SchacterDL, VillemagneVL,McLeanCA,ReardonK,BoydA,LewisV, KlugG,JonesG,BaxendaleD,MastersCL,RoweCC, Rosen B, Albert M. 2003. fMRI studies of associative et al. 2009. 11C-PiB PET studies in typical sporadic encoding in young and elderly controls and mild AD Creutzfeldt-Jakobdisease.JNeurolNeurosurgPsychiatry patients.JNeurolNeurosurgPsychiatry74:44-50. 80:998-1001. SperlingRA,LaviolettePS,O’KeefeK,O’BrienJ,RentzDM, VincentJL,SnyderAZ,FoxMD,ShannonBJ,AndrewsJR, PihlajamakiM,MarshallG,HymanBT,SelkoeDJ,Hed- RaichleME,BucknerRL.2006.Coherentspontaneous denT,etal.2009.Amyloiddepositionisassociatedwith activityidentifiesahippocampal-parietalmemorynet- impaireddefaultnetworkfunctioninolderpersonswith- work.JNeurophysiol96:3517-3531. outdementia.Neuron63:178-188. VincentJL,PatelGH,FoxMD,SnyderAZ,BakerJT,Van Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, EssenDC,ZempelJM,SnyderLH,CorbettaM,Raichle LaViolettePS, Vitolo OV, Hedden T, Becker JA, Rentz ME.2007.Intrinsicfunctionalarchitectureintheanaes- DM, Selkoe DJ, et al. 2010. Functional alterations in thetizedmonkeybrain.Nature447:83-86. memorynetworksinearlyAlzheimer’sdisease.Neuro- molecularMed12:27-43. VisserPJ,KesterA,JollesJ,VerheyF.2006.Ten-yearriskof dementia in subjects with mild cognitive impairment. SternY,AlexanderGE,ProhovnikI,MayeuxR.1992.Inverse Neurology67:1201-1207. relationship between education and parietotemporal Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, perfusiondeficitinAlzheimer’sdisease.AnnNeurol32: Rossor M. 2000. Diagnosis and management of Alz- 371-375. heimer’s disease and other disorders associated with SternEA,BacskaiBJ,HickeyGA,AttenelloFJ,LombardoJA, dementia.TheroleofneurologistsinEurope.European HymanBT.2004.Corticalsynapticintegrationinvivois Federation of Neurological Societies. Eur J Neurol 7: disruptedbyamyloid-bplaques.JNeurosci 24:4535- 133-144. 4540. WalhovdKB,FjellAM,AmlienI,GrambaiteR,StensetV, Thiel CM, Henson RN, Morris JS, Friston KJ, Dolan RJ. Bjornerud A, Reinvang I, Gjerstad L, Cappelen T, 2001. Pharmacological modulation of behavioral and Due-Tonnessen P, et al. 2009. Multimodal imaging in neuronalcorrelatesofrepetitionpriming.JNeurosci21: mildcognitiveimpairment:Metabolism,morphometry 6846-6852. anddiffusionofthetemporal-parietalmemorynetwork. TohkaJ,ReilhacA.2008.Deconvolution-basedpartialvol- Neuroimage45:215-223. ume correction in Raclopride-PET and Monte Carlo Wishart HA, Saykin AJ, McDonald BC, Mamourian AC, comparison to MR-based method. Neuroimage 39: FlashmanLA,SchuschuKR,RyanKA,FadulCE,Kasper 1570-1584. LH.2004.Brainactivationpatternsassociatedwithwork- Tolboom N, van der Flier WM, Yaqub M, Boellaard R, ing memory in relapsing-remitting MS. Neurology 62: VerweyNA,BlankensteinMA,WindhorstAD,Scheltens 234-238. P,LammertsmaAA,vanBerckelBN.2009.Relationship WolkDA,PriceJC,SaxtonJA,SnitzBE,JamesJA,LopezOL, of cerebrospinal fluid markers to 11C-PiB and 18F- AizensteinHJ,CohenAD,WeissfeldLA,MathisCA,etal. FDDNPbinding.JNuclMed50:1464-1470. 2009. Amyloid imaging in mild cognitive impairment Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, subtypes.AnnNeurol65:557-568. WattjesMP,RaijmakersPG,BarkhofF,ScheltensP,Her- WongDF,RosenbergPB,ZhouY, KumarA, Raymont V, holzK,LammertsmaAA,etal.2010.Molecularimaging RavertHT,DannalsRF,NandiA,BrasicJR,YeW,etal. inthediagnosisofAlzheimer’sdisease:Visualassessment 2010. In vivo imaging of amyloid deposition in Alz- of [11C]PIB and [18F]FDDNP PET images. J Neurol heimerdiseaseusingtheradioligand18F-AV-45(flobeta- NeurosurgPsychiatry81:882-884. pirF18).JNuclMed51:913-920. CitethisarticleasColdSpringHarbPerspectMed2012;2:a006213 23 gro.enicidemnisevitcepsrep.www
